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ABSTRACT 
 
The Role of Estrogen Receptors in the Contribution of Constrictor Prostanoids to Aortic 
Coarctation-Induced Hypertension.  
(December 2008) 
Minga Miown Sellers, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. John N. Stallone 
 
This study investigated the effects of selective estrogen receptor (ER) agonists on 
constrictor prostanoid (CP) function and on the development of mean arterial pressure 
(MAP) in aortic coarctation-induced hypertension (ACIH).  Female Sprague-Dawley rats 
were divided randomly into four groups: intact (INT), ovariectomized (OVX), OVX + 
ERα selective agonist (4, 4’, 4”-(4-Propyl-[1H]-pyrazole-1, 3, 5-triyl)trisphenol; 
OVX+PPT), or OVX + ERβ selective agonist (2,3-bis(4-Hydroxyphenyl)-propionitrile; 
OVX+DPN). Rats were then subjected to abdominal aortic coarctation (hypertensive, 
HT) or sham surgery (normotensive, NT). PPT, DPN or vehicle treatments were given 
daily as a subcutaneous injection. MAP was measured every other day at 2-14 days after 
coarctation. Mesenteric arterioles were harvested 12-14 days after coarctation for 
isometric tension studies to examine concentration-responses to VP. Basal and VP-
stimulated prostanoid release and mRNA and protein levels of ERα and ERβ (using real 
time RT-PCR and immunoblotting) were measured in separate groups of arterioles. MAP 
was higher in INT-HT, OVX+PPT-HT and OVX+DPN-HT than in OVX-HT after 12 
days. Vascular reactivity to VP was greater in OVX+PPT-NT rats than in other groups. 
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There were no significant differences in vascular reactivity to VP in HT groups. Blockade 
of thromboxane receptor (TP) with SQ 29,548 (TP receptor antagonist) did not have a 
significant effect in any groups. Inhibition of intracellular calcium release with 
simvastatin (blocker of IP3 mediated calcium release) was greater in NT than in HT 
groups, and greater in OVX- and DPN-treated groups than in INT and PPT-treated 
groups. VP-stimulated release of thromboxane (TXA2) and prostacyclin (PGI2) were 
highest in INT-HT and OVX+PPT-HT rats. Neither mRNA nor protein expression of 
ERs changed significantly in response to selective ER agonist treatment or during 
hypertension. Selective ERα stimulation with PPT during development of ACIH resulted 
in similar effects to those seen in INT rats for CP release, VP reactivity of mesenteric 
arterioles and MAP, while selective stimulation of ERβ only increased MAP. While ERα 
is capable of modulating most of the effects of estrogen on the vasculature, ERβ has 
stimulatory effects on MAP during the development of ACIH that merit further 
investigation. Further studies of the vascular actions of ERα and ERβ may lead to better 
hormonal therapies that successfully prevent and/or treat cardiovascular disease in post-
menopausal women.  
 
 
 
 
 
 
 v
DEDICATION 
 
To my husband, Ryan Sellers, for supporting me both intellectually and financially in my 
quest for higher education. To Mary Wheat, for inspiring me to work hard and to be the 
best I can be in every situation and for teaching me that nothing can keep me down. To 
my family, who made me strive for more. 
 
 vi
ACKNOWLEDGEMENTS 
 
I owe a debt of gratitude to my doctoral advisor Dr. John N. Stallone for his 
support and encouragement throughout this project.  His mentorship made it possible for 
me to endure, even though at times I wanted to quit. I would also like to thank the other 
members of my committee, Dr. Janet Parker, Dr. Farida Sohrabji and Dr. Cris Heaps for 
their guidance and clarification throughout this project. Very special thanks goes to 
Millie Mattox for teaching me how to use a myograph and answering my many, many 
questions. Very special thanks goes to Dr. Emily Wilson for the use of her lab space for 
my molecular biology studies, and to her students and technicians for teaching me the 
delicate procedures involved in molecular biology. I would like to thank Dr. Wendy 
Baltzer for teaching me surgical methods and for her friendship and encouragement. I 
would also like to thank Jennifer Crawford and Stephanie Hampe for their help with 
many experiments and company in the lab. The help of Feng Xu in many of my 
experiments is greatly appreciated; I don’t know what I would have done without her. I 
would like to thank my dogs, Bruiser, Bailey, Bennie, Tia and Bling Bling and my cats, 
Bandito, Federali, Ho Chi Minh, Leon and Bunnicat and my birds Peanut Butter and 
Rocko for giving me something furry and feathery to love and hug when I got home after 
a long, hard day, and for putting a smile on my face and making me laugh.  Finally my 
thanks goes to the Department of Veterinary Physiology and Pharmacology for their 
support and for never making me feel inferior. Thank you so much for this opportunity.  
 
 vii
TABLE OF CONTENTS 
 
              Page 
ABSTRACT ............................................................................................................... iii 
DEDICATION ........................................................................................................... v 
ACKNOWLEDGEMENTS ....................................................................................... vi 
TABLE OF CONTENTS ........................................................................................... vii 
LIST OF FIGURES ................................................................................................... x 
LIST OF TABLES ..................................................................................................... xiv 
CHAPTER 
 I INTRODUCTION AND HISTORICAL REVIEW ....................................... 1 
 1.1  Introduction ..................................................................................... 1 
 1.2  Classical Effects of Estrogen .......................................................... 2 
  1.2.1 Estrogens in the Reproductive System ............................... 2 
  1.2.2 Estrogens in Other Systems ................................................ 5 
  1.2.3 Estrogens in the Vascular System ....................................... 6 
  1.2.4 Hormone Replacement Therapy ......................................... 6 
 1.3  The Actions of E2 on the Vasculature ............................................. 10 
  1.3.1 Regulation of Estrogen Receptors ...................................... 12 
  1.3.2 Mechanisms of Estrogen Receptor Actions ........................ 13 
  1.3.3 The Effects of E2 on Intracellular Calcium ......................... 15 
  1.3.4 The Effects of E2 on Arachidonic Acid Metabolism .......... 18 
  1.3.5 Mechanism of Action for TXA2 and PGI2 .......................... 21 
 1.4  Recent Findings – Deleterious Effects of Estrogens ....................... 23 
 1.5  Aortic Coarctation-Induced Hypertension ...................................... 26 
 
 II MATERIALS AND METHODS ..................................................................... 28 
 2.1  Animals ........................................................................................... 28  
  2.1.1 Animal Preparation ............................................................. 29 
  2.1.1.1 Blood Samples for Estrogen and Estrone  
              Measurement ..............................................................     30  
  2.1.1.2 Vaginal Smears .......................................................... 30 
  2.1.2 Preparation for Aortic Coarctation-Induced Hypertension . 30 
 
 
 viii
CHAPTER                                                                                                             Page 
  
2.2  Measurement of Mean Arterial Pressures ....................................... 31 
 2.3  Preparation of Isolated Mesenteric Arterioles ................................ 31  
 2.4  Vascular Function ........................................................................... 32  
 2.5  Evaluation of Basal and Agonist-Stimulated PGI2 and TXA2  
   Production ....................................................................................... 34  
 2.6  RNA and Protein Extraction from Rat Mesenteric Arterioles  ....... 34  
 2.7  Real Time RT-PCR ......................................................................... 37  
  2.7.1 First-Strand cDNA Synthesis (Reverse Transcriptase) ....... 37 
   2.7.2 Real Time PCR ................................................................... 38 
 2.8  Immunoblot ..................................................................................... 38 
 2.9  Radioimmunoassay (RIA) of 6-keto-PGF1α, TXB2, Estradiol  
and Estrone...................................................................................... 40 
 2.10 Data Analysis ................................................................................... 41 
 2.11 Chemicals ......................................................................................... 42 
 III OBJECTIVES AND RATIONALE ............................................................ 44 
 3.1  Objectives ....................................................................................... 44 
 3.2  Experimental Design  ...................................................................... 45 
  3.2.1 Specific Aim I ..................................................................... 45 
   3.2.1.1 Rationale .................................................................... 45 
  3.2.1.2 Specific Aim I Experiments ....................................... 46 
  3.2.2 Specific Aim II .................................................................... 47 
  3.2.2.1 Rationale .................................................................... 47 
  3.2.3 Specific Aim III .................................................................. 48 
  3.2.3.1 Rationale .................................................................... 48 
                                                                                                                                                                        
 IV RESULTS .................................................................................................... 51 
4.1  Effects of Aortic Coarctation-Induced Hypertension on Plasma  
 Estradiol and Estrone levels  ........................................................... 51 
 4.2  Effects of Aortic Coarctation-Induced Hypertension and Estrogen  
 Receptor Agonists on Mean Arterial Pressure ................................ 59 
 4.3  Effects of Aortic Coarctation and Estrogen Receptor Agonists on  
 TXA2 and PGI2 Release from Mesenteric Arterioles ..................... 61 
  4.3.1 TXA2 ................................................................................... 61 
  4.3.2 PGI2 .....................................................................................  64  
  4.4  Effects of Aortic Coarctation and Estrogen Receptor Agonists on  
    the Mesenteric Arteriole Response to Arginine Vasopressin ......... 66 
  4.4.1 Effects of SQ 29,548 on the Vasopressin Concentration- 
   Response .............................................................................     71 
  4.4.2 Effects of Simvastatin on Mesenteric Arteriole Responses  
   to Vasopressin  .................................................................... 80 
 
 ix
CHAPTER                                                                                                             Page 
 
 4.5  Effect of Estrogen Receptor Agonists on Thoracic Aorta Responses  
   to Vasopressin  ................................................................................... 88 
 4.6  Effect of Aortic Coarctation-Induced Hypertension and Estrogen  
  Treatment on Estrogen Receptor Expression ..................................... 91 
  4.6.1 Real Time RT-PCR ............................................................. 91 
  4.6.2 Immunoblots ....................................................................... 94 
 
V SUMMARY AND DISCUSSION ................................................................     98 
 5.1  Effects of Aortic Coarctation-Induced Hypertension on Plasma  
  Estradiol and Estrone Levels ............................................................. 100 
 5.2  Effects of Aortic Coarctation-Induced Hypertension and Estrogen  
  Receptor Agonists on Mean Arterial Pressure  .................................. 101 
 5.3  Effects of Aortic Coarctation and Estrogen Receptor Agonists on  
 TXA2 and PGI2 Release from the Mesenteric Vasculature ............... 104 
  5.3.1 TXA2 ................................................................................... 105 
  5.3.2 PGI2   ................................................................................... 106 
 5.4  Effects of Aortic Coarctation and Estrogen Receptor Agonists on 
    the Mesenteric Vascular Responses to Arginine Vasopressin ........... 108 
  5.4.1 Effects of SQ 29,548 on Concentration Responses to  
   Vasopressin ......................................................................... 111 
 5.4.2 Effects of Simvastatin on Concentration Responses to   
Vasopressin  ........................................................................ 113  
 5.5  Effect of Estrogen Receptor Agonists on the Concentration  
   Response to Vasopressin in Rat Aorta ............................................... 115 
 5.6  Effect of Aortic Coarctation-Induced Hypertension and Estrogen  
                Treatment on Estrogen Receptor Expression ..................................... 116 
  5.6.1 Real Time RT-PCR ............................................................. 116 
  5.6.2 Immunoblots ....................................................................... 117 
 5.7  Conclusions ........................................................................................ 118 
 
REFERENCES .......................................................................................................... 121 
VITA .......................................................................................................................... 138 
 
 x
LIST OF FIGURES 
 
FIGURE                                                                                                                        Page 
 1 Synthesis of estrogens from cholesterol ..................................................... 4 
 
 2 Vasoconstrictor and vasodilator mechanisms in the endothelium and  
vascular smooth muscle .............................................................................. 9 
 
 3 Mechanisms of estrogen action ................................................................... 14 
 
 4  Calcium signaling mechanisms................................................................... 17 
 
 5 Mechanism of vascular smooth muscle contraction ................................... 18 
 
 6 Arachidonic acid metabolites ...................................................................... 21 
 
7  Plasma estradiol concentrations in normotension and during the  
  development of hypertension in intact female rats ..................................... 53 
 
8 Plasma estrone concentrations in normotension and during the  
development of hypertension in intact female rats ..................................... 54 
 
9 Plasma estradiol concentrations in normotension and during the  
development of hypertension in OVX-NT and OVX-HT female rats ........ 55 
 
10 Plasma estrone concentrations in normotension and during the  
development of hypertension in OVX-NT and OVX-HT female rats ........ 56 
 
11  Plasma estradiol concentrations in normotension and during the 
development of hypertension in OVX+ER-NT and OVX+ER-HT  
female rats ................................................................................................... 57 
 
12 Plasma estrone concentrations in normotension and during the  
development of hypertension in OVX+ER-NT and OVX+ER-HT  
female rats ................................................................................................... 58 
 
13  Mean arterial blood pressures (MAP) of rats following sham  
coarctation or induction of aortic coarctation-induced hypertension  
at days 2 and 12........................................................................................... 60 
 
14 Basal and vasopressin-stimulated release of TXA2 from mesenteric  
arterioles in normotensive and aortic coarctation-induced  
hypertensive rats .........................................................................................     63 
 
 xi
FIGURE                                                                                                                        Page 
 
15 Basal and vasopressin-stimulated release of PGI2 from mesenteric  
arterioles in normotensive and aortic coarctation-induced  
hypertensive rats .........................................................................................     65 
 
16 Concentration-response curves for arginine vasopressin in 
endothelium-intact mesenteric arterioles from INT, OVX,  
OVX+PPT- and OVX-+DPN-treated normotensive-control  
and hypertensive Sprague-Dawley rats .......................................................     67 
 
17 Concentration-response curves for arginine vasopressin in  
endothelium-intact mesenteric arterioles from OVX-PPT-  
and OVX-DPN-treated normotensive-control and aortic  
coarctation-induced hypertensive Sprague-Dawley rats .............................    69 
 
18 Concentration-response curves for arginine vasopressin in  
 endothelium-intact mesenteric arterioles from INT-NT female  
 Sprague-Dawley rats in the presence of SQ 29,548 or vehicle-control  .....     71 
 
19  Concentration-response curves for arginine vasopressin in 
 endothelium-intact mesenteric arterioles from OVX-NT female  
 Sprague-Dawley rats in the presence of SQ 29,548 or vehicle-control ...... 72 
 
20  Concentration-response curves for arginine vasopressin in  
 endothelium-intact mesenteric arterioles from OVX+PPT-NT  
 Sprague-Dawley rats in the presence of SQ 29,548 or vehicle-control ...... 73 
 
21  Concentration-response curves for arginine vasopressin in  
endothelium-intact mesenteric arterioles from OVX+DPN-NT  
Sprague-Dawley rats in the presence of SQ 29,548 or vehicle-control ...... 74 
 
22  Concentration-response curves for arginine vasopressin in  
endothelium-intact mesenteric arterioles from INT-HT  
Sprague-Dawley rats in the presence of SQ 29,548 or vehicle-control ...... 75 
 
23  Concentration-response curves for arginine vasopressin in  
endothelium-intact mesenteric arterioles from OVX-HT  
Sprague-Dawley rats in the presence of SQ 29,548 or vehicle-control ......     76 
 
24  Concentration-response curves for arginine vasopressin in  
endothelium-intact mesenteric arterioles from OVX+PPT- 
treated HT Sprague-Dawley rats in the presence of SQ 29,548  
or vehicle-control ........................................................................................ 77 
 
 
 xii
FIGURE                                                                                                                        Page 
 
 
25 Concentration-response curves for arginine vasopressin in  
 endothelium-intact mesenteric arterioles from OVX+DPN- 
treated HT Sprague-Dawley rats in the presence of SQ 29,548  
or vehicle-control ........................................................................................ 78 
 
26 Concentration-response curves for arginine vasopressin in  
 endothelium-intact mesenteric arterioles from OVX+PPT- 
treated NT Sprague-Dawley rats in the presence of Simvastatin 
 or vehicle-control ....................................................................................... 81 
 
27 Concentration-response curves for arginine vasopressin in  
endothelium-intact mesenteric arterioles from OVX+DPN- 
treated NT Sprague-Dawley rats in the presence of Simvastatin  
or vehicle-control  .......................................................................................     82 
 
28  Concentration-response curves for arginine vasopressin in 
endothelium-intact mesenteric arterioles from INT-HT  
Sprague-Dawley rats in the presence of Simvastatin 
 or vehicle-control ....................................................................................... 83 
 
29 Concentration-response curves for arginine vasopressin in  
 endothelium-intact mesenteric arterioles from OVX-HT  
 Sprague-Dawley rats in the presence of Simvastatin  
 or vehicle-control ........................................................................................     84 
 
30  Concentration-response curves for arginine vasopressin in  
endothelium-intact mesenteric arterioles from OVX-PPT- 
treated HT female Sprague-Dawley rats in the presence of  
Simvastatin or vehicle-control .................................................................... 85 
 
31   Concentration-response curves for arginine vasopressin in  
endothelium-intact mesenteric arterioles from OVX-DPN- 
treated HT female Sprague-Dawley rats in the presence of  
Simvastatin or vehicle-control .................................................................... 86 
 
32  Concentration-response curves for arginine vasopressin in 
endothelium-intact aortic ring segments from OVX+PPT- 
treated NT Sprague-Dawley rats in the presence of  
Simvastatin, SQ 29,548 or vehicle-control ................................................. 89 
 
 
 
 
 xiii
FIGURE                                                                                                                        Page 
 
33 Concentration-response curves for arginine vasopressin in  
 endothelium-intact aortic ring segments from OVX+DPN- 
 treated NT Sprague-Dawley rats in the presence of  
 Simvastatin, SQ 29,548 or vehicle-control ................................................. 90 
 
34 Effect of hypertension and estrogen receptor agonists on mRNA levels of 
estrogen receptor alpha ............................................................................... 91 
 
35 Effect of hypertension and estrogen receptor agonists on mRNA levels of 
estrogen receptor beta ................................................................................. 93 
 
36  Effect of hypertension and estrogen receptor agonists on the expression of 
estrogen receptor alpha ............................................................................... 95  
 
37 Effect of hypertension and estrogen receptor agonists on the expression of 
estrogen receptor beta ................................................................................. 96 
 
38 Representative immunoblot analysis of ERα, ERβ and beta actin  
in mesenteric arterioles ............................................................................... 97 
           
    
            
    
 
  
xiv
LIST OF TABLES 
 
TABLE                                                                                                                          Page 
 
 1 Hormone production and turnover in adult women .................................... 5 
 
2 Body and uterine weights of intact, ovariectomized, ovariectomized  
 with estrogen replacement, ovariectomized with PPT treatment  
 and ovariectomized with DPN treatment Sprague-Dawley rats ................. 52 
 
3  Maximal contractile responses to vasopressin and sensitivity to VP for 
 vehicle-control and SQ 29,548 treated mesenteric arterioles ..................... 79 
 
4 Maximal contractile responses to vasopressin and sensitivity to VP for  
 vehicle-control and simvastatin treated mesenteric arterioles .................... 87
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
 
 
CHAPTER I 
 
INTRODUCTION AND HISTORICAL REVIEW 
 
 
1.1 Introduction 
 
Men are from Mars, women are from Venus. Well, maybe that is a bit extreme. 
Although men and women do hail from the same planet, the fact remains that there are 
many differences between the sexes, ranging from behavior to body function to aging. 
And the culprit for these differences? We suspect the sex steroid hormones: estrogens and 
androgens. Perhaps once thought to affect only reproductive function, it is now well 
known that these hormones affect nearly every facet of the body, from brain 
development, to skeletal growth, to cardiovascular function.  
With respect to the cardiovascular system, considerable dogma has developed 
surrounding the effects of estrogens on cardiac and vascular functions. For many years it 
was thought that estrogens, particularly 17β-estradiol, exerted beneficial effects on the 
cardiovascular system and when estrogens vanished at menopause, so did their beneficial 
effects, resulting in increased incidences of cardiovascular diseases. This would certainly 
explain why premenopausal women experience much less cardiovascular disease (CVD) 
than men, and why after menopause, the incidences of CVD increase rapidly in women 
and attain levels virtually identical with those of men. This dogmatic view was based 
largely on epidemiological studies of coronary artery disease and hypertension in men 
versus women; however more recent clinical and epidemiological studies of other CVD  
____________________ 
This dissertation follows the style and format of the American Journal of Physiology – 
Heart and Circulatory Physiology. 
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strongly suggest that estrogens exert deleterious effects on the vasculature.  
Indeed, diseases of vascular origin such as Raynaud’s disease and primary 
pulmonary hypertension occur more frequently in young premenopausal women than in 
men and appear to be estrogen dependent. Thus this doctoral dissertation will focus on 
cellular and  
molecular mechanisms underlying the deleterious effects of estrogen on vascular function 
in the female.  
 
1.2 Classical Effects of Estrogens  
1.2.1 Estrogens in the Reproductive System 
The estrogens are naturally occurring C18-steroids characterized by the presence 
of an aromatic A-ring, a phenolic hydroxyl group at C-3, and either a hydroxyl group 
(estradiol) or a ketone group (estrone). As with all major classes of steroid hormones, the 
estrogens are derived from the common precursor molecule cholesterol (Fig. 1). The 
main estrogen secreted by the ovary is 17β-estradiol (E2), which is derived from its 
immediate precursor, testosterone, by the action of the enzyme aromatase. It is the most 
potent and important of the estrogens. In addition, the weaker androgen androstenedione 
is converted to estrone (E1) in the ovary, the secondary bioactive form of estrogen, also 
by the action of aromatase. E1 is also secreted from the ovary, and while less potent than 
E2, can exert many similar effects. While less E1 is secreted from the ovary, it remains in 
equilibrium in the circulation with E2, due to 17β-hydoxysteroid dehydrogenase activity, 
which reversibly converts E2 to E1. Then, E1 and E2 are converted to the primary estrogen 
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metabolite estriol (E3) by the liver; E3 is also secreted in small amounts by the ovary. 
Additionally, E1 is the major remaining estrogen in the circulation after menopause (see 
Table 1 for production rates in pre-menopausal women).  
The main roles of the estrogens are the development and maintenance of the 
female reproductive system and include: growth and hypertrophy of the uterus and 
vagina, development of the secondary sex characteristics, and development of the ductal 
system of the breast. Estrogens also play a central role in the regulation of the menstrual 
cycle and the process of ovulation. Production and secretion of E2 by the ovarian follicle, 
stimulated by follicle stimulating hormone (FSH), causes circulating plasma E2 levels to 
rise 5- to 9-fold (Table 1). The sharp increase in E2 release from the dominant follicle 
triggers a surge in gonadotropins (FSH and luteinizing hormone, LH), resulting in 
ovulation. Estrogens also inhibit the growth of cohort follicles and prepare the fallopian 
tubes for transport of the ovum and zygote (146). 
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Figure 1: Synthesis of estrogens from cholesterol. Adapted from Ganong, 
Review of Medical Physiology 22nd edition (45).   
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Table 1: Hormone production and turnover in adult women (adapted from Berne and 
Levy eds. Physiology, 4th edition) (11).  
Steroid 
Plasma 
Concentration 
(ng/dl) 
Production Rate 
(µg/day) 
Metabolic 
Clearance Rate 
(L/day) 
Estradiol 6-50 80-700 1400 
Estrone 5-20 100-500 2200 
Progesterone 100-1000 2000-25000 2200 
    
 
 
1.2.2 Estrogens in Other Systems 
Estrogen receptors (ERs) are found in nearly every tissue type in the body and 
thus, the effects of estrogens are widespread and have been observed in nearly every 
organ system. Estrogens act directly and indirectly on bone osteoclasts and resorptive 
cytokines, respectively, to inhibit bone resorption. E2 stimulates reabsorption of sodium 
from the renal tubules. In addition, a number of proteins synthesized in the liver are 
increased by estrogens; these include angiotensinogen, the hormone-binding globulins, 
very-low-density lipoproteins and high-density lipoproteins.  
Estrogens also exert effects in the brain and nervous system. Estrogens exert 
actions on several regions of the nervous system, including those involved with higher 
cognitive function, pain mechanisms, mood, susceptibility to seizures and even fine 
motor skills (83). There is also evidence that 17β-estradiol has neuroprotective effects in 
relation to stroke (9, 143) and Alzheimer’s disease (125) in pre-menopausal women. In 
addition, there are nonnuclear ERs located in glial cells, dendrites, and presynaptic 
terminals. These nonnuclear ERs may couple with various second messenger systems to 
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regulate various cellular events (83). These neuroprotective effects of estrogens in the 
brain are attributed largely to increases in endothelial nitric oxide synthase (eNOS) and 
the resultant formation of nitric oxide (NO) in the brain vasculature and the possible 
maintenance of the integrity of the blood brain barrier (25, 42, 46, 47, 125).  
 
1.2.3 Estrogens in the Vascular System 
The well known effects of estrogens (especially E2) on the vasculature are 
generally viewed as beneficial. E2 has effects on both the endothelium and vascular 
smooth muscle (VSM), and usually acts as a vasodilator. It increases the release of 
vasodilators such as nitric oxide (NO), prostaglandin E2, and prostacyclin, while 
decreasing production and activity of endothelin-1, a potent vasoconstrictor. In addition, 
E2 stimulates the growth and migration of endothelial cells, while simultaneously 
inhibiting the growth of VSM cells. E2 also enhances angiogenesis by facilitation of basic 
fibroblastic growth factor (bFGF) (112) and vascular endothelial growth factor (61, 77).  
 
1.2.4 Hormone Replacement Therapy 
If the loss of estrogens lead to increases in CVD in women, then it follows that 
replacement of estrogens will prevent or decrease the incidence of CVD. A number of 
earlier studies demonstrated beneficial effects of estrogens on CV health and disease. For 
example, in vitro treatment with E2 inhibits Ca2+ influx in VSM cells, causing relaxation 
of arterial strips from male rats, and this effect was shown to be endothelium independent 
(50). In studies of human coronary arteries in vitro, E2 produced relaxation by increasing 
VSM levels of cAMP and cGMP (91). In one clinical study, infusion of physiological 
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levels of E2 potentiated endothelium-dependent vasodilation in healthy post-menopausal 
women and endothelium-dependent and –independent vasodilation in post-menopausal 
women with impaired vascular function and risk factors for atherosclerosis (48). Another 
study in primates with surgical menopause (OVX) and diet-induced coronary artery 
atherosclerosis showed that coronary arteries constricted in response to acetylcholine, but 
20 minutes after infusion of ethinyl estradiol, the coronary arteries relaxed in response to 
acetylcholine (145). However, several recent clinical trials involving various types of 
hormone replacement therapy (HRT) reported that HRT was not protective against a 
variety of CVD, including atherosclerosis, pulmonary embolism (PE), myocardial 
infarction, stroke and venous thrombosis (51, 58, 111). Indeed, the incidences of CVD 
(nonfatal myocardial infarction and coronary heart disease death) and breast cancer were 
increased with HRT (111). The Heart and Estrogen/Progestin Replacement Study 
(HERS) studied women who had previous CHD, but no previous venothrombosis. The 
primary outcome for this study was increased incidence of coronary heart disease (CHD), 
either nonfatal myocardial infarction or CHD-related death in healthy postmenopausal 
women (no CHD prior to the trial) and a three-fold increase in risk for thromboembolic 
events in the HRT group (51). The Women’s Health Initiative (WHI) trial was terminated 
early because it was clear that the risks of HRT significantly outweighed the benefits 
(111). The primary outcome of the WHI study was increased incidence of CHD, either 
nonfatal myocardial infarction or CHD death, in women that were postmenopausal and 
healthy (no CHD prior to the trial). Both of these studies used conjugated equine 
estrogens (CEE) combined with medroxyprogesterone acetate (MPA). There is some 
controversy concerning the use of CEE as the source of estrogen replacement, because it 
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is not the endogenous hormone 17-β estradiol. Arguments have been made that 
replacement of the missing hormone with the identical endogenous compound rather than 
CEE would result in the return of the protective effects on CV health. The Women’s 
Estrogen-Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-
HART) looked at the effects of E2 either alone or with MPA on the progression of 
coronary-artery atherosclerosis and found that neither estrogen alone nor estrogen with 
sequentially administered MPA had any effect to reverse established atherosclerosis in 
women 20 years post-menopause, but that E2 treatment could reduce the extent of 
atherosclerosis if HRT is initiated at the beginning of menopause (58). It was recently 
found that MPA can disrupt estrogen metabolism and abrogate the inhibitory effects of E2 
on the VSM cells (35). The findings of Dubey et al. (35) concerning the actions of 
progesterone on E2 should come as no surprise, as progesterone modulates the actions of 
estrogen, both by decreasing ER levels and reducing nuclear bound estrogen-receptor 
complexes (146).  
These recent studies on HRT only seem to add to the confusion surrounding the 
mysterious effects of estrogen. What are the pathways affected by estrogens that lead to 
the beneficial versus detrimental effects on the vasculature?  
 
 
 
 
 
 
 
 9
 
 
 
 
 
 
 
 
 
Vascular  
Smooth Muscle 
Cell Contraction 
Vascular  
Smooth Muscle 
Cell Relaxation 
Endothelial 
Cell 
Renin 
ATG AT1 
AI 
M
ACh 
COX 
TxS Endothelial 
Cell 
TP 
TXA2/PGH2 ATII 
AT1R 
COX 
PGIS 
PGI2 
IP 
cAMP 
eNOS 
NO 
cGMP 
L-Arg 
AVP 
V1R 
IP3 IP3 
Figure 2: Vasoconstrictor and vasodilator mechanisms in the endothelium and vascular 
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1.3 The Actions of E2 on the Vasculature 
E2 exerts effects on both the endothelium and VSM, involving function and 
growth of the vascular wall (Fig. 2). Perhaps the most well known vascular effect of E2 is 
on the nitric oxide (NO) pathway. An abundance of research in this area shows that E2 
enhances NO not only by its genomic action to increase the message for the enzyme that 
catalyzes formation of NO, endothelial nitric oxide synthase (eNOS), but also by 
enhancing the level of eNOS activation (20). The effects on eNOS levels occur at the 
level of gene transcription via ERs, while the enhanced activation of eNOS is a rapid, 
non-genomic effect. There is a subpopulation of ERα that localizes to caveolae (lipid 
ordered domains on the plasma membrane of endothelial cells that contain signal 
transduction molecules) and is coupled with eNOS. E2 stimulates the tyrosine 
kinase/MAPK and PI3 kinase pathways and phosphorylates eNOS, resulting in its rapid 
activation (20). More recently it was discovered that ERβ also has nongenomic actions on 
eNOS in endothelial cell caveolae and rapidly increases eNOS activity in the presence of 
E2 (21).  
Numerous studies have established that E2 increases prostacyclin (PGI2) synthesis 
and activity of the cyclo-oxygenase (COX) pathway in various tissues (47, 62, 117). E2 
also appears to be involved in a number of thromboxane (TXA2)-dependent vascular 
diseases such as Raynaud’s disease (101, 139), primary pulmonary hypertension (109) 
and pre-eclampsia, all of which involve excessive vasoconstriction and elevated vascular 
production of TXA2. The incidence of Raynaud’s disease is up to seven-fold higher in 
women than in men (139), while that of primary pulmonary hypertension is about four-
fold higher in women than men (68, 140). Similarly, in pre-eclampsia there is an 
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unfavorable shift in the balance between PGI2 and TXA2 (148), resulting in a greater 
prominence of TXA2 during pregnancy. The balance between these two prostanoids is 
crucial, not only for the regulation of vascular tone, but also for hemostasis (16, 39).  
The effects of E2 on the prostanoid pathway have been elucidated further in more 
recent studies. Reactivity of the rat thoracic aorta to VP is substantially greater in females 
than in males or ovariectomized females, and estrogen replacement therapy (ERT) of 
OVX females restores reactivity to VP to that of the intact female. Selective blockade of 
various prostanoid pathway enzymes and/or receptors revealed that constitutive forms of 
COX-2 and thromboxane synthase (TXS) exist in the vasculature, and the greater 
production constrictor prostanoids (CP), mainly TXA2, are responsible for the enhanced 
responsiveness to VP in females (72, 73). Estrogen enhances the release of and reactivity 
to CP in the female vascular wall and blockade of the pathway reduces reactivity to VP 
by 25-30%. These effects of E2 are mediated by increased expression of COX-2, TXS, 
and TP receptor (73).  
E2 also is known to increase intracellular calcium (IC) release in the endothelium 
but to decrease extracellular Ca2+ entry into VSM (50, 89, 93, 113, 124). Reactivity of the 
female rat aorta to VP was reported to be more dependent on the release of IC, while that 
of the male aorta is more dependent on extracellular calcium entry (36).  
In addition to the effects of E2 on the vasculature, E1, the less potent estrogen 
secreted by the ovary, exerts both genomic and non-genomic effects on the vascular wall 
via ERα and ERβ (108, 118), including increasing NO synthesis (via activation of 
mitogen activating protein kinase – MAPK; a non-genomic effect) and enhancing protein 
kinase C (PKC) activity and VSM cell proliferation (a genomic effect), as well as 
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increasing COX, thromboxane, and prostacyclin activity via the phospholipase C – IP3-
diacylglycerol – PKC signal transduction pathway (a non-genomic effect) (108, 118).  
 
1.3.1 Regulation of Estrogen Receptors 
E2 exerts most of its long-term (genomic) effects through the two known cytosolic 
steroid estrogen receptors (ER), alpha (ERα) and beta (ERβ). Rapid (non-genomic) 
effects occur via cell membrane-associated steroid receptors and can occur through either 
ER, as both have been shown to localize to the plasma membrane (21) and are coupled to 
rapid-acting signal transduction pathways. The expression of ERs by both the VSM and 
endothelium of the vascular wall is well documented (1, 3, 10, 21, 28, 57, 60), however, 
the extent of their actions on the vascular wall is a subject that has barely been scratched 
on the surface. 
ERs appear to be highly regulated and their expression is variable among different 
blood vessels. For example, E2 treatment decreases expression of ERα in vena cava of 
OVX rats, but has no effect on ERα expression in thoracic and abdominal aorta (86). In 
contrast, in cerebral arteries, ERT with E2 increases ERα gene expression while OVX 
decreases its expression (86). There is a significant decrease in the expression of 
cerebrovascular ERβ receptors with OVX, and while ERT with E2 treatment upregulates 
ERα in the cerebrovasculature, it has no effect on ERβ gene expression (86). 
The mechanisms underlying the effects of E2 on ER expression appear to involve 
two distinct mechanisms. First, ERs can be altered by autologous downregulation, where 
an activated ER interacts with its own gene sequence to decrease its mRNA by 
suppressing transcription (86). Second, ERs can also be targeted by ubiquitin, a small 
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protein which marks the protein to which it attaches for degradation by the 26S 
proteasome (86). In this manner, ER proteins are decreased without altering their mRNA. 
Additionally, the ERα gene can be methylated and inactivated; thus, ERs may be affected 
by growth factors and hormone signals (86).  
 
1.3.2 Mechanisms of Estrogen Receptor Actions 
Most of the actions that estrogens exert throughout the body can be linked to their 
receptors, ERα and ERβ. The ERs are classical cytosolic steroid receptors, which require 
that estrogens bind and activate the receptors. The activated receptor-ligand complexes 
then translocate to the nucleus, and then form either homodimers or heterodimers and 
bind to estrogen response elements (ERE) located within the regulatory region of the 
target genes. Binding of the EREs activates transcription (formation of messenger RNA), 
then translation, resulting in increases or decreases in protein synthesis, which mediate 
the biological actions of the estrogens. ERs can also interact with other transcription 
factors, such as activator protein-1 (AP-1) or Sp1 transcription factor instead of the 
classical ERE; however, not all of the actions of estrogens can be attributed to genomic 
activity (Fig. 3). More recently, membrane-bound ERs have been identified, which are 
coupled to G-proteins, as well as so called estrogen receptor-related receptors (ERRs), 
some of which do not actually bind estrogen, but can actually activate transcription and 
even interact with traditional ERs (14, 53). The membrane-ERs can rapidly exert their 
actions without inducing transcription, and are reported to modulate ion channels, G 
protein-coupled receptors, tyrosine kinases, and mitogen-activated protein kinases (56, 
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86, 93). Membrane-bound ERs also activate phospholipase C and adenylyl cyclase signal 
transduction pathways (86).  
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Figure 3: Mechanisms of estrogen action. Adapted from Hewitt et al., 
2005 (56). (A) Estrogen binds a nuclear receptor and activates 
transcription, either through ERE (classical mechanism) or AP-1/Sp1 
(nonclassical mechanism). (B) Estrogen binds a plasma membrane 
bound receptor and activates any one of multiple signaling pathways 
(C). ER = estrogen receptor, ERE = estrogen response element, ERR = 
estrogen receptor-related receptor (also in the nucleus), AP-1 = 
 
 15
1.3.3 The Effects of E2 on Intracellular Calcium 
E2 exerts effects on intracellular calcium (IC) release as well as extracellular Ca2+ 
entry via various calcium (Ca2+) channels in a variety of tissues (113, 124, 135, 151). In 
the vasculature, the findings are rather conflicting. Some studies report that acute E2 
treatment increases IC release (113), while others show that acute E2 decreases cytosolic 
Ca2+ levels (104). These conflicting findings may reflect differences in the tissues studied 
and/or the experimental preparations employed, for example, as some studies have 
utilized cultured cells (113, 124, 135), while others studied intact vessels (36). Most 
studies observe rapid (nongenomic) effects of E2 to increase IC in endothelial cells (89) 
or genomic effects to down regulate L-type Ca2+ channel expression in VSM (93). At 
present, it appears that only very few studies have investigated the individual effects of 
ERs on the various Ca2+ channels (151). 
E2 exerts its effects on cytosolic Ca2+ via the vascular wall using one of two 
mechanisms. Rapid non-genomic effects occur when E2 interacts with membrane ERα or 
ERβ  or with another receptor capable of binding E2, and then activating rapid cell 
signaling pathways and causing changes in cytosolic [Ca2+] (increasing or decreasing, 
depending on the cell type) within seconds to minutes. In contrast, the “classical” 
genomic effect occurs when E2 binds to its cytosolic receptor(s) and mediates mRNA 
transcription for vascular Ca2+ ion channels, such as decreases in expression of the L-type 
Ca2+ channel in VSM (136). Indeed, E2 has differing effects on calcium handling in 
different cells within the same tissue. For instance, E2 acutely inhibits L-type Ca2+ ion 
channel fluctuation in VSM cells (93), while increasing release from intracellular stores 
in endothelial cells (89, 113). 
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The cytosolic Ca2+ concentration is very important to the mechanism of 
contraction in VSM. An increase in Ca2+ ion can occur by release from intracellular 
stores, namely, the sarcoplasmic reticulum (SR) and/or by extracellular entry through 
membrane Ca2+ channels (Fig. 4). Once in the cytosol, the free Ca2+ ion binds to 
calmodulin and the calcium-calmodulin complex in turn activates myosin light chain 
kinase (MLCK). MLCK phosphorylates myosin light chains in the presence of ATP, and 
this phosphorylation allows the myosin heads to form a cross bridge with the actin 
filaments, resulting in shortening of the VSM cell, and thereby producing contraction 
(Fig. 5). In VSM, contractile force is graded so that the higher the cytosolic [Ca2+], the 
greater VSM contraction that results. 
In the endothelium, activation of eNOS is dependent upon intracellular Ca2+ 
concentration (66). Similarly, prostanoid synthesis by the endothelium is also a Ca2+ 
dependent process, due to sensitivity of phospholipase A2 to Ca2+ (23). Therefore, the 
effects of E2 on the IC pathway could be crucial to the understanding of the multifaceted 
and complicated effects of E2 on the vascular wall.  
 
 
 
 17
 
 
 
 
 
 
 
Ca2+-permeant 
channels 
Voltage gated (L-
type - found in 
VSM), ligand gated 
PLC 
DAG PIP2 
IP3 
Extracellular 
Cytoplasm 
Sarcoplasmic or 
endoplasmic reticulum 
Ca2+ 
Ca2+ 
Ca2+ 
Ca2+ 
IP3R 
(Found in both 
VSM and Endo) 
Ca2+ 
Ca2+ 
Ca2+ 
Ca2+ 
Ca2+ Ca2+ 
RyR 
Ca2+ 
PIP2 
GPCR 
G protein 
 
GTP GDP 
SR 
Membrane 
Figure 4: Calcium signaling mechanisms. (adapted from Clapham 2007) 
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additional Ca2+ release from RyR and IP3R. GPCR activates PLC to form IP3 
and DAG from PIP2. IP3 activates IP3R to trigger Ca2+ release from SR. PIP2, 
phosphatidylinositol 4,5 bisphosphate; DAG, diacyl glycerol; PLC, 
phospholipase C; GPCR, G protein coupled receptor; GTP, guanosine 
triphosphate; GDP, guanosine diphosphate; IP3, inositol triphosphate; IP3R, 
inositol triphosphate receptor; RyR, ryanodine receptor. 
Cell 
Membrane 
Agonists, such 
as TXA2 
 
 18
SR 
Ca2+ Channels 
Ca2+ Calmodulin +
Ca2+ -- Calmodulin 
+ 
MLCK 
-
MLC 
P 
Phosphatase 
ATP 
cAMP 
 
 
 
           
Figure 5: Mechanism of vascular smooth muscle contraction. 
(Adapted from Cardiovascular Physiology Concepts, Klabunde, 
2004) (67). Calcium ions enter the smooth muscle cell and 
combine with calmodulin. The calcium-calmodulin complex 
along with ATP activates myosin light chain kinase, which 
phosphorylates the myosin head and enables it to bind with actin. 
Ca2+, calcium ion; SR, sarcoplasmic reticulum; MLC, myosin 
light chain; MLCK, myosin light chain kinase; ATP, adenosine 
triphosphate; cAMP, cyclic adenosine monophosphate; P, 
phosphorylation. 
 
 
 
 
 
 
 
1.3.4 The Effects of E2 on Arachidonic Acid Metabolism 
The initial step in arachidonic acid (AA) metabolism is its liberation from 
membrane glycerophospholipids through the action of phospholipase A2 (PLA2) or 
diacylglyceride (DAG) lipase. The liberated AA is then metabolized to prostaglandin 
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endoperoxide G2 (PGG2) and then to prostaglandin endoperoxide H2 (PGH2) by the 
enzyme cyclo-oxygenase. PGH2 is then converted to a variety of bioactive prostaglandins 
(PGs) by their respective terminal PG synthases to form PGI2 (prostacyclin synthase; 
PGIS), PGD2, PGE2 and PGF2α (mixed isomerases) and to TXA2 (thromboxane 
synthase; TXS). The PG synthases exhibit cell- and tissue-specific distributions, resulting 
in specific profiles of PG production. The liberation of AA from the cell membrane is the 
rate-limiting step in prostanoid biosynthesis, but much of the research on AA metabolism 
is focused on the cyclo-oxygenase (COX) enzymes, because they are expressed in several 
different isoforms and the fact that these enzymes are the primary targets for 
pharmacological inhibition. COX-1 is localized to the endoplasmic reticulum and is 
constitutively expressed in many tissues, including the vascular wall, and it is the only 
isoform expressed in platelets. The prostanoids derived from COX-1 are involved in the 
maintenance of normal physiological homeostasis (“housekeeping” functions). COX-2 is 
localized mainly in the nuclear envelope, and is traditionally considered the “inducible” 
form, as its expression is increased in response to mitogens, endotoxins and 
proinflammatory cytokines. Recent research has identified a constitutive form of COX-2 
in the kidney and aorta (73, 97, 102).  
Similar to other areas of research on the effects of E2, there is conflicting evidence 
concerning the effects of E2 on the PG pathway. The effects of E2 on COX-1, COX-2, 
and PGI2 have been studied extensively in various tissues, while the effects of E2 on 
TXA2 and TP receptor have been studied only to a limited extent. It is possible that the 
apparent conflicts in the evidence for the actions of E2 may in fact reflect differential 
effects of E2 in different tissues. For example, E2 upregulates COX-1 expression in rat 
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cerebral vessels (47) and in ovine fetal pulmonary arterial endothelium (62), but does not 
affect COX-1 expression in endothelium or VSM in rat aorta (73). Since PGIS is the most 
abundant prostaglandin synthase enzyme in most vascular beds, COX-1 is the enzyme 
traditionally linked with increases in PGI2 production in the vascular wall. However, 
recent studies have shown that COX-2, PGI2 and TXA2 are upregulated in parallel in 
intact female rats, compared to male or ovariectomized female rats, whereas COX-1 is 
unchanged (73). This recent finding suggests not only the presence of a constitutive form 
of COX-2, but the possibility that PGI2 can also formed by COX-2. In light of this more 
recent evidence regarding regulation of the COX-2 enzyme and its association with 
TXA2, function of the prostanoid biosynthesis pathway and its regulation by E2 must be 
reconsidered. Because both PGI2 and TXA2 share a common precursor (PGH2; see Fig. 6) 
and their respective enzyme (PGIS and TxS) as well as COX-2 are all upregulated by E2, 
the vascular actions of E2 are more complex than previously recognized, since they 
involve simultaneous upregulation of both PGI2 and TXA2 production by the vascular 
wall. Thus, it is becoming increasingly apparent that the effects of E2 on the vasculature 
are dynamic and complicated.  
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Figure 6: Arachidonic acid (AA) metabolites. Adapted from Moncada 
and Higgs, 1986 (90). 
EETs
PGD2 PGF2α 
PGE2 
Arachidonic Acid 
Cyclic Endoperoxide 
G2 
(Prostaglandin G2) 
Prostaglandin H Synthase 
 (Cyclo-oxygenase Function) 
Cyclic Endoperoxide 
H2 
(Prostaglandin H2) 
Prostaglandin H Synthase 
(Hydro-peroxidase Function) 
Leukotrienes
Lipoxygenase 
Pathway 
P450 
Pathway 
Thromboxane Synthase 
Thromboxane A2 
Thromboxane B2 
Non-Enzymatic 
Hydrolysis
Prostaglandins 
PG 
Isomerases 
Prostacyclin Synthase 
Prostaglandin I2 
(Prostacyclin) 
Non-Enzymatic 
Hydrolysis 
Prostaglandin F1α 
 
1.3.5 Mechanism of Action for TXA2 and PGI2 
The prostanoid receptors as a group belong to the heterotrimeric G-protein-
coupled rhodopsin-type superfamily (15).  The TXA2 receptor (TP) is a Gq-type G-
protein, which when occupied by its ligand, activates phospholipase C (PLC-β), which in 
turn cleaves phosphatidylinositol 4,5 bisphosphate (PIP2) to form 1,4,5-inositol 
triphosphate (IP3) and diacylglycerol (DAG) (15). IP3 then binds to IP3 receptors on the 
sarcoplasmic reticulum to stimulate the release of intracellular Ca2+ into the cytosol (see 
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Fig. 4). DAG acts as an additional second messenger, which remains in the cellular 
membrane and activates one of several isoforms of protein kinase C (PKC). In turn, PKC 
phosphorylates target proteins leading to the various cellular effects of TXA2. Mitogen-
activated protein (MAP) kinases such as extracellular signal-related kinase 1 and 2 
(ERK1/2) and p38 kinase also have been linked to TP stimulation (13, 15). There is also 
some evidence that p38 mitogen-activated protein kinase (p38 MAP kinase) is required 
for TXA2 induced contraction in rat resistance arteries (12).  
The PGI2 receptor (IP) is a Gαs-type G-protein. IP stimulation leads to activation 
of adenylyl cyclase and accumulation of the second messenger cyclic AMP (cAMP), and 
this in turn leads to activation of cAMP-dependent protein kinase (PKA). PGI2 is the 
predominant AA metabolite produced by endothelial cells and there is conflicting 
evidence about which COX enzyme is responsible for its production (COX-1 or -2) (39, 
41, 64, 82).  
In 1983, Moncada et al. proposed that the balance between PGI2 and TXA2 was 
important to maintaining hemostasis in the circulation (90). More recently it was shown 
that IP knock-out mice show enhanced platelet activation and vascular proliferation in 
response to vascular injury (24). TXA2 biosynthesis is increased in wild-type mice after 
vascular injury, and this response is further enhanced in the IP knock-out mice (24). 
There is also growing evidence of cross talk between IP- and TP-dependent signaling 
pathways: TP agonists stimulate PGI2 release from the endothelium, TP desensitization 
causes sensitization to IP agonists and IP activation evokes TP desensitization (24). It is 
becoming more evident that the proper balance between TXA2, PGI2 and possibly other 
 
 23
metabolites of the AA pathway is complex and crucial to the maintenance of normal 
vascular homeostasis. 
 
1.4 Recent Findings – Deleterious Effects of Estrogens 
Recently it was determined that the non-selective COX inhibitor indomethacin 
(Indo) attenuates the contractile responses to vasopressin (VP) and to the α-adrenergic 
agonist phenylephrine (PE) in female but not male rat aorta (43). Contractile responses to 
VP and PE in the female rat aorta also are attenuated by the PGH2/TXA2 receptor 
antagonist SQ 29,548, suggesting that CP play a significant role in the regulation of tone 
in the normal female vasculature, but play little or no role in the normal male vasculature. 
Sex differences in constrictor responses to the thromboxane mimetic U-46619 also occur 
in the rat aorta (72). The contractile responses of the female aorta to U-46619 are 
significantly higher than those of male aorta, and OVX markedly attenuates while E2 
replacement restores responses to U-46619, revealing that E2 enhances reactivity to TP 
agonists (72).  
The prominent sex differences in reactivity to VP in the rat aorta are clearly 
estrogen dependent, since INT and E2 replaced (ER)-OVX female Sprague-Dawley rats 
are more reactive to VP than OVX females or males (43, 72). Reactivity to VP in the 
female rat aorta is enhanced by CP and it appears that COX-2 is the isoform responsible 
for CP synthesis in the aorta, as COX-2 selective inhibitors such as NS-398 and niflumic 
acid attenuate reactivity to VP to the same extent as the non-selective COX inhibitor Indo 
(41% and 47% vs. 43% respectively) (72).  
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The greater effects of CP in the female vasculature are associated with estrogen-
enhanced expression of COX-2, thromboxane synthase (TXS) and TP receptor mRNA in 
both Endo and VSM of the female aorta, whereas estrogen-dependent differences in the 
expression of COX-1 mRNA were not observed (73). Immunohistochemical (IHC) 
studies of the aorta revealed that expression of COX-1 protein in Endo and VSM did not 
differ among male, intact female, OVX female or OVX-ER females, whereas COX-2 and 
TXS staining were higher in Endo and VSM of intact and OVX-ER females, compared to 
males and OVX females (73).  
The cellular and molecular effects of estrogen on the COX pathway in the female 
rat aorta are paralleled by functional changes in the release of TXA2 and PGI2, which are 
higher in INT and OVX-ER females, than in males or OVX females (73). In contrast, 
radio-immunoassay (RIA) of basal prostanoid release does not differ between sexes or in 
OVX vs. INT females (73). The prostanoid release data, coupled with the mRNA 
expression and IHC data clearly reveal that estrogen enhances both the production of and 
the reactivity to CP in the normotensive female rat aorta.  
If the activity of the entire TXA2 pathway is upregulated by E2 in the 
normotensive female rat (compared to the male rat), what are the consequences of this 
sex difference in CP function during pathophysiological states such as hypertension? Of 
particular interest, what are the consequences of these sex differences in CP function in 
models of hypertension that are dependent on the TXA2 pathway? Aortic coarctation-
induced hypertension (ACIH) is just such a model of hypertension. Ligation of the 
abdominal aorta (see section 1.3) results in a markedly lower blood pressure in the left 
than the right kidney, enhancing the release of renin by the left kidney and the formation 
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of angiotensin II (ANG II) and CP. The acute phase of ACIH (12-14 days) exhibits 
marked increases in vascular tone due to increases in reactivity to ANG II and ANG II-
stimulated CP release, mainly TXA2 (75). 
Recent studies on the sexual dimorphism of the CP pathway in ACIH reveal that 
INT female rats do indeed exhibit exacerbated hypertension in response to ACIH. During 
the acute phase of ACIH (12-14 days), the MAP of female hypertensive (F-HT) rats 
continues to increase over the entire time period to 186 ± 7 mmHg. In contrast, in male 
hypertensive (M-HT; 160 ± 4 mmHg) and ovariectomized female hypertensive (OVX-
HT; 150 ± 8 mmHg) rats, MAP plateaus at lower levels between days 6 and 10 (6, 7). 
Estrogen replacement of OVX-F hypertensive rats (OVX+ER-HT) restores MAP (171 ± 
3 mmHg) to levels comparable to those of INT females (6, 7). Further, during an acute 
i.v. infusion of SQ 29,548, F-HT and OVX+ER-HT exhibited marked decreases in MAP 
of 50-60 mmHg, while M-HT and OVX-HT decreased only 20-22 mmHg. Chronic daily 
oral treatment with Ridogrel (TxS and TP receptor antagonist) during the development of 
ACIH produces a 40-60 mmHg decline in MAP in F-HT and OVX+ER-HT, while M-HT 
and OVX-HT exhibited a minimal decline in MAP (6, 7). These data reveal that the CP 
pathway is largely responsible for the higher pressures in the F-HT and OVX+ER-HT 
rats, that the TXA2 pathway is active in the resistance arterioles responsible for the 
regulation of MAP, and that E2 plays a significant role in the regulation of CP pathway 
function and blood pressure in this model of hypertension. 
In vitro prostanoid release studies in the thoracic aorta reveal that basal TXA2 
release does not differ between M and F during NT; however, in response to ANG II, 
TXA2 release is nearly 2-fold higher in F than in M aortas. During the acute phase of 
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ACIH, there is a 7-fold increase in basal TXA2 release in F compared to NT, while M 
only exhibits a 4-fold increase (6, 7). Therefore, basal release of TXA2 during 
hypertension is nearly 2-fold higher in F than in M aorta, and ANG II stimulated release 
remains 28% higher in F than in M aorta. 
PGI2 release in ACIH is slightly more variable than TXA2. There were no 
differences in basal release between F and M in NT controls; however, ANG II 
stimulation of the aorta did not increase PGI2 release, in contrast to TXA2 release. During 
the acute phase of ACIH, basal release of PGI2 is 1.5-fold higher in F than in M, and 
ANG II stimulation produces a small increase in PGI2 release in F, while there is no 
change in M (6).  
While it is clear that E2-dependent CP function is enhanced to a much greater 
extent in F than in M during the development of ACIH, several important issues 
regarding the relationship between E2, CP function, and blood pressure remain 
unanswered. Specifically, what are the effects of the individual ERs on the CP pathway, 
the development of ACIH, and HT-associated changes in vascular function? It is also not 
known whether arterioles (100-200 µm) show similar trends of TXA2 and PGI2 release in 
response to VP, and whether the individual ERs have differing effects on arteriolar 
function or the development of hypertension. 
                                                                                                                                                                 
1.5 Aortic Coarctation-Induced Hypertension 
The model of hypertension known as aortic coarctation-induced hypertension was 
chosen for the present studies for two reasons. First, it is well known that ACIH is a 
renin-dependent and CP-dependent form of hypertension (5, 70, 74). To produce this 
 
 27
model, the aorta is completely ligated between the renal arteries, resulting in decreased 
arterial pressure in the left kidney, and subsequently a dramatic increase in renin release. 
This renin release results in downstream increases in angiotensin II (ANG II). ANG II 
acts directly on the vasculature to cause vasoconstriction; in addition, it stimulates 
generation of TXA2 by the vascular wall, increasing local and plasma levels of TXA2 (87, 
144). Second, it is a form of hypertension in which female rats develop markedly higher 
MAP than males (7). The higher MAP results from the effects of estrogen on the CP 
pathway, vascular function and structure. When females are OVX, the MAP and TXA2 
production are much lower and is similar to that seen in male rats. Thus, ACIH is a 
relevant model to study the vascular actions of E2 and CP involved in the development of 
hypertension. 
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CHAPTER II 
MATERIALS AND METHODS 
2.1 Animals 
Female Sprague-Dawley rats (14-16 weeks old at time of study, Harlan; Houston, 
TX) were used in all studies. Animals were housed in vivarium facilities at the College of 
Veterinary Medicine and Biomedical Sciences with controlled temperature (22-24°C), 
relative humidity (~50%), and lighting (12:12-h light-dark cycle). Animals were housed 
in pairs in standard plastic laboratory rat cages. Tap water and rat chow (HarlanTek-lad 
Global Diet; 16% protein) were provided ad libitum. This special diet is free of 
phytoestrogens, which are common in standard rat chow and have been reported to 
confound the effects of ovariectomy on vascular reactivity (28, 50). All experiments were 
reviewed and approved by the Texas A&M University Small Animal Care Committee 
(SACC).  
NT and HT rats were divided randomly into ten experimental groups: intact 
normotensive females (F-NT), ovariectomized normotensive females (OVX-NT), 
estrogen receptor alpha agonist-treated OVX normotensive females (OVX+PPT-NT), 
estrogen receptor beta agonist-treated normotensive females (OVX+DPN-NT), 
ovariectomized normotensive females with 17-β estradiol replacement pellets (OVX+ER-
NT), intact hypertensive females (F-HT), ovariectomized hypertensive females (OVX-
HT), estrogen receptor alpha agonist-treated hypertensive females (OVX+PPT-HT), 
estrogen receptor beta agonist-treated hypertensive females (OVX+DPN-HT) and 
ovariectomized hypertensive females with 17-β estradiol replacement pellets (OVX+ER-
HT). Previous studies established that contractile responses to vasopressin and 
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phenylephrine did not vary during various stages of the estrous cycle; therefore, intact 
female vessels were studied without regard to phase of the estrous cycle (2). 
 
2.1.1 Animal Preparation 
At 6 weeks of age, half of the female rats were subjected to bilateral OVX using 
standard surgical methods (see section 2.0.2 for anesthetic procedure). OVX rats 
remained untreated, or received estrogen replacement therapy (ER) with 17-β estradiol 
time-release pellets (2 pellets/rat; 0.05 mg/60-day pellet, 17-β estradiol), or with an ERα 
selective agonist (4, 4’, 4”-(4-Propyl-[1H]-pyrazole-1, 3, 5-triyl)trisphenol; PPT, 410-
fold selectivity of ERα over ERβ) (129a), or with an ERβ selective agonist (2,3-bis(4-
Hydroxyphenyl)-propionitrile; DPN, 70-fold selectivity of ERβ over ERα) (86a), or 
vehicle treatment. 17β-estradiol pellets were placed approximately 1 week prior to 
coarctation or sham surgery and no sooner that 4 weeks following OVX, although for 
most rats, there was a 6-8 week interval from OVX to pellet implantation. PPT and DPN 
treatments were started 1-2 days prior to coarctation or sham surgery, both to acclimatize 
the rats to the injection and to ensure stable circulating plasma levels at the time of 
surgery. PPT and DPN were dissolved in DMSO, and then diluted 1:10 in corn oil for 
daily subcutaneous injection. Vehicle alone (1:10 DMSO in corn oil) was used in the 
vehicle control-treated groups (INT-F and OVX-F). The final concentration of PPT and 
DPN in solution was 0.5 mg/ml. Each rat received 0.10 mg/day of PPT or DPN (0.20 ml) 
injection each day for 13-15 days. Vehicle treated rats received 0.2 ml of vehicle alone. 
Treatment times were similar in all groups receiving PPT or DPN.  
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2.1.1.1 Blood Samples for Estradiol and Estrone Measurement 
Blood samples were taken on the day of (but before) pellet implantation and one 
week after pellet implantation on the day of ACIH (or sham surgery) in OVX and 
OVX+ER as well as days 4, 7 and 10 after ACIH or sham surgery. In INT, surgeries were 
performed and the day of diestrus, and blood samples were taken on the subsequent days 
of diestrus (approx. every 4 days). Plasma 17β-estradiol and estrone levels were 
measured in these groups using specific RIA kits for 17β-estradiol and estrone. 
 
2.1.1.2 Vaginal Smears  
Vaginal smears were performed each day on INT-F to determine phase of the 
estrous cycle. 
 
2.1.2 Preparation for Aortic Coarctation-Induced Hypertension  
Aortic coarctation or sham surgery was performed at 12-14 weeks age. Rats were 
given a subcutaneous injection of atropine (25 µg/ml) as a pre-anesthetic at a dose of 0.05 
mg/kg. Rats were then anesthetized with an IP injection of a solution of Ketamine (55 
mg/kg) and Chloral Hydrate (180 mg/kg). After the animals achieved a stable plane of 
surgical anesthesia, the abdominal aorta between the renal arteries was exposed and 
ligated with silk 4-0 suture using sterile surgical procedures. In sham coarcted animals, 
the aorta was dissected free but not ligated. A chronic indwelling catheter (Micro-
Renathane-033 tubing) was placed in the right carotid artery in some groups of animals 
for measurement of mean arterial pressure. Since rats were prone to catheter tampering, 
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custom vests were placed around the chest of the animal to secure the catheters and 
protect them from damage from chewing.  
 
2.2 Measurement of Mean Arterial Pressures 
Rats used in BP studies were trained in small restrainer boxes (9 x 3.5 x 3.5 in.) 
that allowed for free movement but prevented the rats from tampering with the catheters. 
The rats were trained for approximately 2 weeks prior to surgery for the measurement of 
arterial blood pressure (MAP). Using the chronically implanted carotid artery catheters, 
MAP was measured every other day for twelve days post-coarctation or sham surgery. 
The catheters were connected to a pressure transducer (Model DTX, Becton-Dickinson) 
and pressures recorded continuously on a Gould Model 2400S chart recorder. The rats 
were allowed a 10 minute adjustment period in the restraint box before the pressures were 
recorded. After the adjustment period, MAP and heart rate (HR) were recorded for 30 
minutes and averaged. 
 
2.3 Preparation of Isolated Mesenteric Arterioles 
Rats were euthanized via rapid decapitation at 12-14 days post-coarctation. The 
entire mesentery was removed and immediately placed in chilled, (4°C) gassed (95% 
O2/5% CO2) KHB solution for function studies or in chilled RNALater for molecular 
studies. Vessels were immediately dissected free of surrounding fat and connective tissue 
prior to being used in vessel function (myograph) or PG release, or placed in RNALater 
at -20°C (molecular studies) as described below. First and second order arterioles 
(approx. 150-200 µm) branching off the superior mesenteric artery were used in all 
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myograph and PG release studies. The entire mesenteric arcade was used in all molecular 
studies.    
 
2.4 Vascular Function 
Rats were euthanized by rapid decapitation and the entire mesentery and small 
intestines were then removed rapidly en bloc and placed in chilled, (4°C) gassed (95% 
O2/5% CO2) KHB. The intestines and mesentery were then placed in fresh buffer in a 
Petri dish, along with a frozen cube of KHB to ensure that the solution remained at 4°C 
during the entire dissection procedure. First and second order mesenteric arteries were 
cleaned of fat and connective tissue under a dissecting binocular microscope (Olympus 
SZ), taking care not to stretch or damage the vessels in any way. Once cleaned of 
connective tissue and fat, the arteries were then cut away from the mesenteric arcade and 
placed in fresh, cold KHB. Using a Filar eyepiece micrometer, the arteries were then cut 
into four segments approximately 1.50 mm long each. The vessels were allowed to rest in 
cold, gassed KHB for 45 minutes to an hour prior to mounting on the myograph.  
After resting, each vessel segment was mounted on a wire myograph (Danish 
Myotechnology) for force-tension studies. Each 1.50 mm vessel segment was placed on 
the foot of a myograph chamber and a 40 µm diameter piece of stainless steel wire was 
passed through the lumen of the vessel, taking care not to tear or damage the smooth 
muscle or endothelium. The wire was then secured under a screw at the top of the left 
foot of the myograph. The wire was then stretched straight across the left foot of the 
myograph and then secured at the bottom screw of that same foot, thereby positioning the 
vessel vertically. A second wire was passed through the lumen of the vessel and then 
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secured at the top and bottom screws of the right foot. The feet were then adjusted so that 
the two wires were parallel throughout the length of the vessel. The wires were then 
stretched just to the point of touching the endothelium without stretching the vessel. 
Measurements were then made for vessel segment length, internal diameter and wall 
thickness using an ocular micrometer. The myograph chambers were then placed on the 
main block of the myograph for recording tension and heating the bath to 37°C. 95% 
O2/5% CO2 was bubbled into the myograph chambers continuously throughout the 
experiment. Once all four chambers were connected, the chambers were then drained and 
refilled with 6 mL of fresh KHB, gassed and warmed to 37°C. The resting tension-
internal circumference relationship was determined for each vessel using progressive 
stretches (50 µm per stretch) and measurements of passive tension and internal vessel 
circumference (L) at each level of stretch. L was calculated by using the following 
formula: L = 2f + 4 D/2 + 2(πD/2), which reduces to L = 2f + D (2 + π), where D is wire 
diameter and f is the distance between the wires as measured by the ocular micrometer 
(92). Once L was determined, the vessels were stretched to L95, where L95 is 0.95 L100 and 
L100 is the internal circumference the artery would have under a transmural pressure of 
100 mmHg (92). For the hypertensive groups, the transmural pressures were set at 0.95 
L150 for OVX females, and 0.95 L180 INT, PPT or DPN females, respectively. The L 
values were based on the average MAP measured in those groups of rats at 12 days post 
aortic coarctation prior to sacrifice. A contractile response to phenylephrine                
(PE; 2x10-6M) was used to determine smooth muscle viability and a subsequent dilation 
response to acetylcholine (ACh; 10-6M) was used to determine endothelial integrity. 
Myograph chambers were then drained and refilled with fresh, warmed, gassed KHB. 
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The vessels were then allowed to re-equilibrate in the baths for 20 minutes prior to 
pretreatment with inhibitors and/or vehicle-controls added to the baths. Following a 20 
minute pretreatment, a cumulative concentration-response to vasopressin                     
(VP; 10-12 – 10-8) was obtained.  
 
2.5 Evaluation of Basal and Agonist-stimulated PGI2 and TXA2 Production 
Paired adjacent segments of mesenteric feed arteries (2-3 mm long; 150-200 µm) 
were cleaned of all connective tissue and fat, and were then placed into chilled, (4oC) 
gassed (95% O2/5% CO2) KHB solution, allowing the arteries to rest for at least 30-45 
minutes. The arteries were then transferred into 1.5 ml polyethylene microcentrifuge 
tubes with 450 µl KHB, gassed continuously, and gradually warmed up to 37°C. After 
pre-incubation for 30 minutes, the KHB solution was carefully aspirated, then 300 µl of 
either KHB alone (basal) or KHB with VP (10-8 M) was added to the tissues and 
incubated for 45 minutes at 37°C and gassed continuously. After incubation, the KHB 
was collected and stored in -80°C until RIA of the stable metabolites of PGI2 (6-keto- 
prostaglandin F1α; 6-keto-PGF1α) and TXA2 (TXB2). RIA is performed in duplicate for 
each sample. 
 
2.6 RNA and Protein Extraction from Rat Mesenteric Arterioles 
Mesenteries were quickly removed and the arteries, veins and fat were cut away 
from the small intestine. The mesenteric arcade was then placed in ice cold RNALater 
(Ambion) and stored at -20°C for a minimum of three days prior to further dissection. 
Tissues were submerged in cold RNALater (4°C) in a Petri dish that had been cleaned 
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previously with RNaseZap (Ambion) to destroy any RNase present. The Petri dish was 
then placed on a platform of ice during dissection. Arteries were dissected away from fat 
and connective tissue, then placed in fresh RNALater and stored at -80°C until RNA 
isolation.  
Mesenteric arterial tissues were submerged in 1.0 mL of TRI reagent. Tissues 
were homogenized for 15 seconds and then placed on ice for 1 minute; homogenizing and 
icing steps were successively repeated three to four times. The homogenate was 
centrifuged at 14,000 RPM for 5 minutes to remove large cytoskeletal components. The 
supernatant was aspirated and transferred to a new RNase-free tube, 105 µl of 3M sodium 
acetate and 350 µl of bromochloropropane were added, and the contents were mixed and 
placed on ice for 15 minutes. The sample was centrifuged at 12,000 RPM for 5 minutes; 
the aqueous phase was aspirated and transferred to a new RNase-free tube for further 
RNA extraction. The organic phase was aspirated and transferred to a new RNase-free 
tube, 300 µl of 100% ethanol was added and the sample was stored at -20°C for later 
protein extraction. For each mL of the aqueous phase, 1 mL of 
phenol/chloroform/isoamyl alcohol (125:24:1) was added, and the tubes were mixed 
vigorously and centrifuged at 12,000 RPM for 5 minutes. The aqueous phase was again 
aspirated and transferred to a new RNase-free tube, with equal volume of 
phenol/chloroform/isoamyl alcohol (125:24:1), mixed and centrifuged at 12,000 RPM for 
5 minutes. Total RNA was then precipitated by incubating the final aqueous extraction 
with an equal volume of 100% isopropanol at 4°C for 30 minutes. The isopropanol-
extracted mixture was then centrifuged at 14,000 RPM for 30 minutes at 4°C to pellet the 
precipitated RNA. The RNA pellet was then washed with 70% ethanol, dried at room 
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temperature for 5 minutes, and dissolved in RNAStore (Ambion) at -80°C until real time 
RT-PCR was performed. Prior to performing real time RT-PCR, all samples were treated 
with Turbo DNase system (Ambion) to destroy any DNA present in the samples.  
The organic phase samples (for protein analysis) were thawed and centrifuged at 
6000 RPM for 5 minutes at 4°C. The supernatants were removed and incubated with 1.5 
mL of isopropanol for 10 minutes at room temperature. The samples were then 
centrifuged again at 14,000 RPM for 10 minutes at 4°C to pellet the proteins. The pellets 
were then washed with 2 mL of 0.3 M guanidine hydrochloride/95% ethanol solution, 
incubated at room temperature for 20 minutes, and then centrifuged at 11,500 RPM for 5 
minutes at 4°C. This process was repeated 3 times. After the final wash, the pellets were 
air dried for 5-10 minutes at room temperature. Total proteins were dissolved in 10M 
urea while incubating at 50°C.  Lysis buffer was added to the samples prior to storage at  
-80°C. Lysis buffer consisted of: 50 mM Tris (pH 7.4), 150 mM NaCl, 10% glycerol, 1 
mM Na-Orthovanadate (pH 10), 5 µM ZnCl2, 100 mM NaF, 10 µg/ml aprotinin, 1 µg/ml 
leupeptin, 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride and Milli-Q water.  
Amount added depended on the size of the pellet.  
A second method was used for protein extraction in the second half of the study 
when RNA was not required. In this method, freshly removed mesenteries were placed in 
RNALater and placed in the freezer for at least 72 hours prior to dissection. Mesenteric 
arteries were then dissected in fresh ice cold RNALater and the fat, veins and nerve 
bundles were stripped away, leaving the entire mesenteric arcade for protein extraction. 
Mesenteric arcades were stored in fresh RNALater at -80°C until ready for protein 
extraction. 
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Mesenteric arcades were then removed from RNALater and 250 µl of lysis buffer 
was added to the tissue in 4 mL tubes along with a magnetic steel bead. The tissues were 
then ground up in a Fisher high-throughput tissue homogenizer at speed setting 10 for 
approximately 10 minutes. Tubes were removed from the machine at the halfway point (5 
minutes) and placed on ice for 5 minutes to ensure that the tissues did not overheat before 
completing the homogenization for an additional 5 minutes. The tissue homogenates were 
then transferred to 2 mL Eppendorf tubes and centrifuged at 14,000 RPM at 4°C for 30 
minutes. The supernatant was aspirated and transferred to a fresh Eppendorf tube and 
placed in the freezer at -80°C until proteins were quantitated and immunoblots were 
performed.  
 
2.7  Real Time RT-PCR 
The Invitrogen SuperScript III Platinum qRT-PCR with SYBR Green Kit was 
used for all real time RT-PCR assays. Total mRNA was quantitated using the Agilent 
RNA Nano Kit.  
 
2.7.1 First-Strand cDNA Synthesis (Reverse Transcriptase) 
The kit instructions provided by the manufacturer were followed. All tubes were 
placed on ice throughout the preparation procedure. A mastermix of kit components was 
made, including: 2X RT Reaction Mix, RT Enzyme Mix and DEPC-treated water. 12 µl 
of mastermix was added to 300 ng of mRNA in each 200 µl Eppendorf tube. 
Additionally, a separate mastermix which excluded the RT Enzyme Mix was prepared 
and added to tubes with 150 ng mRNA as the external control (RT-). Samples were then 
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placed in a thermocycler and incubated at 25°C for 10 minutes and then incubated at 
42°C for 50 minutes. The reaction was then terminated by incubation at 85°C for 5 
minutes and then chilled on ice. 1 µl of E. coli RNase H was added to each tube and the 
samples were incubated at 37°C for 20 minutes. The samples were then stored at -20°C 
until the real time PCR assay was performed.   
 
2.7.2 Real Time PCR  
Following the protocol from the Invitrogen PCR kit, a mastermix of Platinum 
SYBR Green qPCR SuperMix-UDG, ROX Reference Dye, forward and reverse primers 
and autoclaved distilled water in a total volume of 45 µl was added to each reaction tube. 
5 µl of cDNA from the RT reaction was added to the appropriate reaction tube. Duplicate 
tubes for each RT+ reaction were made. 18S RNA was used as an internal control. Due to 
high expression of 18S RNA, a 1:10 dilution of cDNA from the RT+ tubes was made into 
autoclaved distilled water. 5 µl of this dilution was used in the 18S PCR reaction.  
Following PCR kit instructions, a 3-step cycling program was used for the PCR 
reaction: 50°C for 2 minutes hold, then 95°C for 2 minutes hold, then 45 cycles of 95°C 
for 15 seconds, 55°C for 30 seconds, and 72°C for 30 seconds. PCR Reactions were run 
on ABI Prism 7700 and 7500Fast. The results were exported to a desktop computer and 
saved into an Excel spreadsheet for data analysis.  
 
2.8  Immunoblot  
Total protein was quantitated using the Pierce BCA Protein Assay Kit. After 
quantification, protein samples were combined with sample buffer (1.15 ml distilled H2O, 
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0.42 ml 75% glycerol, 0.63 ml 0.5 M Tris (pH 6.8), 0.25 ml beta-mercaptoethanol (Sigma 
Chemical, St. Louis, MO), 0.05 ml 0.25% bromophenol blue and 0.125 g SDS) and then 
immersed in boiling water (100°C) for 5 minutes to denature the proteins. The sample 
buffer and protein mixture were then loaded onto the SDS-PAGE gels at a volume of    
40 µl.  
40-50 µg of total protein were required to visualize the ERs in the mesenteric 
arteries. The positive controls were human recombinant estrogen receptor β for ERβ and 
uterine protein or MCF-7 whole cell lysate for ERα. Beta actin was used as a loading 
control.  
Proteins were combined with the sample buffer and loaded onto 7.5% Tris-HCL 
pre-cast gels (Bio-Rad). Electrophoresis was performed at 125 V for 75 minutes. After 
the electrophoresis, the gel was teased off into a 0.2% SDS transfer buffer solution, along 
with one piece of filter paper and one sponge. The PVDF membrane was first wet in 
methanol, then rinsed in Milli-Q water and finally placed in transfer buffer with no SDS, 
along with a second piece of filter paper and sponge to be used in the “sandwich”. The 
transfer unit was assembled in the 0.2% SDS transfer buffer solution and transferred 
overnight at constant voltage (12 V). The next morning the transfer unit was 
disassembled and the membrane rinsed in Milli-Q water and dried at room temperature. 
The membranes were stored in a desiccation chamber until the immunoblots were 
performed.  
Prior to incubation with the antibodies, PVDF membranes were soaked in 
methanol. The membranes were then washed in Tris buffered saline (TBS) for 5 minutes 
and then placed in blocking solution (5% non-fat milk in TBST; TBS + 0.1% Tween 20) 
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for a minimum of 2 hours at room temperature. The primary antibodies were then added 
to the milk solution at the following dilutions: ERα 1:200 (rabbit polyclonal, cat. no. sc-
542; Santa Cruz), ERβ 1:500 (mouse monoclonal, cat. no. ab16813; Abcam), and beta 
actin 1:2500 (rabbit polyclonal, cat. no. ab8227; Abcam). The primary antibodies were 
then incubated with the membranes overnight at 4°C on a rocker. The membranes were 
removed from primary antibody solutions, rinsed in TBST for 15 minutes, and then 
rinsed in fresh TBST 2 times for 5 minutes each time prior to placing in the secondary 
antibody solutions. The secondary antibodies were also diluted in 5% non-fat milk in 
TBST at the following dilutions: ERα 1:10.000 (goat anti-rabbit, cat. no. ab6721; Abcam) 
ERβ 1:10,000 (rabbit anti-mouse, cat. no. ab5762; Abcam) and beta actin 1:5,000 (goat 
anti-rabbit, cat. no. ab6721; Abcam). The secondary antibodies were incubated for a 
minimum of 2 hours at room temperature, followed by one 15 minute wash with TBST, 
and then four to six 5 minute washes prior to addition of the substrate for visualization in 
the imaging equipment (Fuji; Model LAS 3000). Substrate (Millipore) was added to the 
blot for 5 minutes. All secondary antibodies were horseradish peroxidase (HRP) 
conjugated.  
 
2.9 Radioimmunoassay (RIA) of 6-keto-PGF1α, TXB2, Estradiol and Estrone 
Basal and VP-stimulated release of prostacyclin and TXA2 by mesenteric 
arterioles into the incubation medium were measured using specific RIAs for the stable 
metabolites 6-keto-prostaglandin  F1α (6-keto-PGF1α) and thromboxane B2  as reported 
previously (72, 126). Briefly, prostanoid standards (1.95-1,000 pg) or unknown samples 
were incubated with [3H]-6-keto-PGF1α or [3H]-TXB2 and with the appropriate 
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prostanoid antiserum overnight at 4°C.  The charcoal-dextran method was used to 
separate bound and free fractions of [3H]-6-keto-PGF1α or [3H]-TXB2. Bound 
radioactivity was counted by liquid scintillation spectroscopy.  The limit of detection of 
the RIAs is 1.95 pg/tube for TXB2 and 3.90 pg/tube for 6-Keto-PGF1α; the cross-
reactivity of the antiserum to other prostanoids is <0.1%, and the intra-assay and 
interassay coefficients of variation are 5.0% and 7.6% respectively (126). 
17β-estradiol was measured using a double-antibody RIA.  Blood samples taken 
to assess plasma estrogen levels were centrifuged and the plasma stored at -80°C until the 
assays were completed. Estrogen standards (0-500 pg/ml) or unknown samples were 
incubated with [I-125]-estradiol and antiserum at room temperature (25°C) for one hour. 
The bound and free fractions were separated using a secondary antibody and 
polyethylene glycol. The intra-assay and interassay coefficients of variation for 17β-
estradiol are 7.1% and 4.6% respectively (Diagnostic Systems Laboratories, Inc.).  
Estrone was measured using a double-antibody RIA. Estrone standards (0-2,000 
pg/ml) or unknown samples were incubated with [I-125]-estrone and antiserum at room 
temperature (25°C) for one hour. The bound and free fractions were separated using a 
secondary antibody and polyethylene glycol. The intra-assay and interassay coefficients 
of variation for estrone are 6.5% and 9.1% respectively (Diagnostic Systems 
Laboratories, Inc.).  
 
2.10 Data Analysis 
All data were expressed as the mean ± standard error with “n” indicating the 
number of animals studied for each experimental treatment group. Prostanoid output is 
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expressed as picograms of 6-keto-PGF1α or TXB2 per mg dry weight of mesenteric 
arterioles. Plasma 17β-estradiol and estrone concentrations are expressed as picograms 
per mL. To detect significant differences among the means of the experimental groups, 
data groups were analyzed by 1-way or 2-way analysis of variance (ANOVA). Factors 
compared for the 2-way ANOVA were sex (F vs. OVX vs. OVX-DPN vs. OVX-PPT or 
F vs. OVX vs. OVX+ER) and experimental treatment (VEH vs. SQ and VEH vs. SIM or 
NT vs. HT). Unpaired t-tests were used to determine significant pair-wise differences 
among the means of the various experimental groups. The Bonferroni test was employed 
to correct for type I error associated with multiple comparisons and differences between 
means were accepted as significant if P<0.05. 
 
2.11 Chemicals 
DPN and PPT were purchased from Tocris Bioscience (Ellisville, MO). 
Phenylephrine hydrochloride and acetylcholine chloride (Sigma Chemical, St. Louis, 
MO) were prepared daily from 10-2 M stock stored at -20°C and diluted in KHB. 
Arginine vasopressin (Sigma Chemical, St. Louis, MO) was prepared daily from 10-3 M 
stock stored at -80°C and diluted in KHB. SQ 29,548 (Cayman Chemical, Ann Arbor, 
MI) was dissolved in 100% ethanol (1 mg/ml), stored at -20°C, and diluted daily with 
KHB. Simvastatin was a generous gift from Merck. ERβ and beta actin primary and 
secondary antibodies were purchased from Abcam (Cambridge, MA) and ERα primary 
and secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). All lysis buffer and immunoblot ingredients were purchased from Sigma Chemical 
or Fisher Scientific (Fair Lawn, NJ) and were of reagent grade quality. RNALater, 
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RNaseZap and TurboDNase were purchased from Ambion (Austin, TX). TRIzol reagent 
was purchased from Invitrogen (Carlsbad, CA).  
SuperScript III Platinum SYBR Green Real time RT-PCR kit and primers were 
purchased from Invitrogen (Carlsbad, CA). Primer sequences were as follows: ERα 
forward: CTG ACA ATC GAC GCC AGA A; ERα reverse: CAG CCT TCA CAG GAC 
CAG AC (GenBank Accession No. Y00102); ERβ forward: CTT GCC CAC TTG GAA 
ACA TC; ERβ reverse: CCA AAG GTT GAT TTT ATG GCC (GenBank Accession No. 
U57439); 18s RNA forward: AAA TGT GGC GTA CGG AAG AC; 18s RNA reverse: 
TTC ACG CCC TCT TGA ACT CT (GenBank Accession No. V01270).  
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CHAPTER III 
OBJECTIVES AND RATIONALE 
3.1 Objectives 
It is apparent that more research needs to be done on the cardiovascular effects of 
estrogen in both males and females. Estrogen appears to exert detrimental effects in 
various states of pathophysiology, and to elucidate these deleterious effects of estrogen 
more clearly, this study will focus on the effects of estrogen and its receptors on the 
vascular wall, both in normotension and during the development of hypertension.  
The central hypothesis to be tested is that:  
 
In aortic coarctation-induced hypertension, estrogen upregulates the 
constrictor prostanoid pathway in the vascular wall via activation of ERβ, enhancing 
vascular tone and leading to enhanced development of hypertension in the female rat.  
 
This hypothesis will be tested by addressing the following specific aims:  
Specific Aim I: To determine the effects of hypertension on plasma 
estradiol levels and estradiol metabolism, and on the expression of estrogen 
receptors in the vascular wall of the rat mesenteric microvasculature.  
Specific Aim II: To determine the mechanisms by which ERα and ERβ 
increase CP pathway function in vascular wall of the rat mesenteric 
microvasculature. 
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Specific Aim III: To determine the roles of ERα and ERβ in mediating 
the effects of estrogen on rat mesenteric arterial vascular function and on systemic 
arterial BP.  
 
3.2   Experimental Design 
3.2.1 Specific Aim I: To determine the effects of hypertension on plasma estradiol 
levels and estradiol metabolism, and on the expression of estrogen receptors 
in the VSM and endothelium in the rat mesenteric microvasculature. 
3.2.1.1 Rationale 
Recent studies reveal that the TxS enzyme is upregulated during aortic 
coarctation-induced hypertension in the aorta (6, 7). In addition, expression of COX-2 
and TxS mRNA in both endothelium and VSM of aorta is higher in both F and OVX+ER 
than in M or OVX females in both normotension and hypertension, while expression of 
TP receptor mRNA is higher in VSM of F and OVX+ER (73). Studies also reveal that 
plasma levels of the sex hormones change during essential hypertension in humans (59, 
65) and that ERβ mRNA is increased after vascular injury in M rat aorta (76), and that 
ERβ mRNA and protein are increased in primate carotid arteries after injury (1). 
However, it is not known whether the message or expression of ERs changes during this 
type of hypertension, or how the ERs are linked to the pathway of TXA2. Studies have 
shown that estrogen regulates the expression of its receptors by up- or down-regulating 
either ER mRNA or protein synthesis (60, 86). There is a possibility that if estrogen 
secretion and/or metabolism are altered during the development of hypertension that the 
expression of ERs will increase or decrease and parallel changes in the TXA2 pathway 
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could occur via this mechanism. Both secretion (in INT-F rats) and metabolism (in 
OVX+ER rats) of 17β-estradiol and estrone will be measured in this study. Finally, this 
specific aim will address the relationship between ER mRNA and protein (transcription 
and translation).  
 
3.2.1.2 Specific Aim 1 Experiments 
Protocol 1: Determine Plasma Estrogen Levels During Normotension and 
Hypertension  
Blood samples were collected from rats on the day of the coarctation surgery 
through the carotid catheter or the jugular vein. Blood samples were then taken on the 4th, 
7th, and 10th days and then on the day of sacrifice (day 12-14) for all OVX and OVX+ER 
groups. For OVX+ER groups, blood samples were also taken 4 weeks post-OVX on the 
day of the E2 pellet placement, prior to pellet implantation to ensure that circulating 
levels of E2 were diminished by OVX. Aortic coarctations were performed in OVX+ER 
groups 2 weeks after pellet placement. For INT females, vaginal smears were performed 
on a daily basis and blood samples were taken during the diestrus phase of the cycle to 
assess basal estrogen levels in the plasma and to avoid the estrogen surge during 
proestrus. 
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Protocol 2: Real Time Reverse-Transcriptase-Polymerase Chain Reaction for 
ERα and ERβ messenger RNA in the Rat Mesenteric Microvasculature  
Mesenteric arcades were collected from INT, OVX and OVX+ER normotensive 
and hypertensive groups and processed to obtain mRNA from each sample, to determine 
the expression of ERα and ERβ mRNA in NT and during the development of HT in 
female rats.  
 
Protocol 3: Immunoblots for ERα and ERβ Protein Expression 
Proteins were extracted from the same samples from which mRNA was obtained.  
 
3.2.2 Specific Aim II: To determine the mechanisms by which ERα and/or ERβ 
increase CP pathway function in VSM and endothelium in the rat mesenteric 
microvasculature. 
 
3.2.2.1 Rationale 
With the recent availability of selective estrogen receptor agonists for ERα and 
ERβ, the effects of each receptor can be studied individually. There are no known studies 
examining chronic effects of treatment with these agonists on cardiovascular function or 
during hypertension. This study provides a unique examination of the selective effects of 
ERα and ERβ during normotension and during the development of hypertension. 
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 Protocol 1: PPT and DPN treatment in vivo. 
OVX rats were randomly assigned into one of three treatment groups: PPT, DPN 
or vehicle treatment. INT rats received vehicle treatment only. Rats were then further 
divided randomly into one of two groups: normotensive or hypertensive. Thus, there were 
eight treatment groups: INT-NT, OVX-NT, OVX+PPT-NT, OVX+DPN-NT, INT-HT, 
OVX-HT, OVX+PPT-HT and OVX+DPN-HT. Based upon these treatments, 
experimental groups include INT females with both ERα and ERβ activity, OVX females 
with little or no ER activity, PPT-treated OVX females with ERα activity only, and DPN-
treated OVX females with ERβ activity only. Rats received subcutaneous injections of 
PPT, DPN or vehicle once a day for 14-16 days.  
 
 Protocol 2: Immunoblots for ERα and ERβ Protein Expression 
Mesenteric arcades were collected from INT, OVX, and PPT- or DPN-treated 
normotensive and hypertensive rats and processed for protein extraction to quantify 
levels of receptor protein expression for ERα and ERβ. 
 
3.2.3 Specific Aim III: To determine role of ERα and ERβ in mediating the effects 
of estrogen on rat mesenteric arterial vascular function and on systemic BP. 
3.2.3.1 Rationale 
In the acute (developmental) phase of ACIH, substantial changes occur both in 
function and structure (remodeling) of the female vasculature (1). TXA2 is a potent 
vasoconstrictor and mitogen that increases vascular tone acutely and induces vascular 
smooth muscle proliferation chronically (8, 15). Thus, increases in TXA2 levels are 
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associated with changes in vascular morphology and function. Inhibition of TXA2 
synthesis or blockade of the TP receptor during ACIH reduces MAP and prevents 
changes in vascular morphology (8). In addition, OVX of female rats prior to the 
induction of ACIH reduces the HT during the acute phase (12-14 days), as well as the 
expression of TxS mRNA, suggesting that TxS and TXA2 levels are increased in parallel 
in the presence of estrogen. In the NT female rat aorta, OVX reduces mRNA and 
expression of TxS and COX-2 and TP receptor. However, the effects of selective 
activation of either ERα or ERβ on MAP, TXA2 production and vascular reactivity to VP 
have not been studied in either NT or ACIH female rats. 
It has been proposed that the balance of TXA2 and PGI2 is crucial to the regulation 
of vascular tone and hemostasis (90, 138, 142). There are several interactions between 
TXA2 and PGI2; including the ability of TP receptor agonists to evoke PGI2 release and 
IP receptor activation to evoke TP receptor desensitization (24).  In light of these 
interactions, the release of PGI2 will also be measured in the mesenteric arteries.  
 
 Protocol 1: PPT and DPN Treatment 
OVX rats were randomly placed into one of three treatment groups: PPT, DPN or 
vehicle treatment. INT rats received vehicle treatment only. Rats were then further 
divided randomly into one of two groups: normotensive or hypertensive. Rats received 
subcutaneous injections once a day for 14-16 days. Uterine weights were recorded to 
assess ERα stimulation in the PPT treatment group. 
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 Protocol 2: Dose Response Curve to Vasopressin 
  First and second order mesenteric arterioles from OVX, PPT, DPN and INT 
normotensive and hypertensive rats were mounted on myographs and a dose response 
curve to VP (10-12 M – 10-8 M) was obtained. Four 1.5 mm sections were cut from each 
artery branch of each animal. Vessels were either incubated in vehicle, SQ 29,548 (1 
µM), or Simvastatin (10 µM or 60 µM).  
 
 Protocol 3: TXA2 and PGI2 Release from Mesenteric Arteries 
First and second order mesenteric arterioles from OVX, OVX+PPT, OVX+DPN 
and INT normotensive and hypertensive rats were incubated in KHB alone or KHB with 
10-8 M VP to obtain basal and agonist-stimulated TXA2 and PGI2 release data.  
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CHAPTER IV 
RESULTS 
4.1 Effects of Aortic Coarctation-Induced Hypertension on Plasma Estradiol and 
Estrone Levels 
Body and uterine weights were recorded on the day of sacrifice. OVX increased 
body weight by an average of 28% and decreased uterine weight by an average of 84%. 
OVX+PPT treatment increased uterine weights compared to OVX (355%), while 
OVX+DPN treatment did not alter uterine weight (see Table 2). The uterus expresses 
ERα protein only, and this measurement served as an index of ERα activity in the PPT 
group.  
Blood samples were taken on the day of coarctation surgery in all groups (day 0), 
and then on the 4th, 7th and 10th day in OVX-F and OVX+ER. In INT rats, all blood 
samples were taken during diestrus on the day of surgery and during the development of 
hypertension. Normotensive INT rats had the expected 4-5 day estrous cycle and low 
range of 17β-estradiol levels during diestrus (7.96 ± 3.08 pg/ml) and most INT rats 
continued to cycle during hypertension (21.24 ± 8.57 pg/ml) (Fig. 7). Hypertension did 
not affect 17β-estradiol levels at matching time points compared to NT (7.77 – 15.64 
pg/ml vs. 7.43 – 21.24 pg/ml) groups (P>0.05). The day to day measurements showed 
similar trends between 17β-estradiol and estrone, but due to fluctuations in both 17β-
estradiol and estrone levels in cycling rats, there were no significant differences within or 
between NT and HT groups, except in INT-HT (estrone, sample 2) (Figs. 7, 8). 
In OVX-NT rats, there was a small but significant decrease in 17β-estradiol levels 
from day 0 (6.82 ± 0.53 pg/ml) to days 4 (3.34 ± 0.35 pg/ml) and 7 (2.92 ± 0.69 pg/ml) 
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(0.0003 ≤ P ≤ 0.001).  Between OVX-NT and OVX-HT groups, 17β-estradiol levels in 
OVX-HT were significantly higher at day 0 (11.12 ± 2.08 pg/ml), day 4 (8.76 ± 2.60 
pg/ml) and day 7 (13.90 ± 3.82 pg/ml) (Fig. 9). There were no significant differences in 
estrone levels between OVX-NT and OVX-HT groups (Fig. 10). 
 
 
Table 2. Body and uterine weights of intact, ovariectomized, ovariectomized with 
estrogen replacement, ovariectomized with PPT treatment and ovariectomized with 
DPN treatment Sprague-Dawley rats. 
 INT OVX OVX+ER OVX+PPT OVX+DPN
n 12 15 18 23 26 
Body Weight 
(grams) 
230.8 ±  
7.5a 
297.2 ± 
9.9b 
255.0 ± 
5.1c 
277.0 ± 
8.0b 
288.9 ± 
8.7b 
Uterine Weight 
(mg/100 g 
body wt.) 
172.2 ± 
12.6a 
26.82 ± 
1.6b -- 
95.7 ± 
 3.3c 
34.42 ± 
3.9b 
      
  
 
 
Note: Values are means ± S.E. (n = number of rats). a-cWithin body weights or 
uterine weights, mean values without common script are significantly different 
(0.0001 ≤ P ≤ 0.0174). 
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Figure 7: Plasma estradiol concentrations in normotension and during the 
development of hypertension in intact female rats. Bars are mean ± S.E. (n = number 
of rats). Samples were taken starting on the day of coarctation and on each day of 
diestrus thereafter. There were no significant differences within INT-NT, INT-HT or 
between NT and HT groups (P > 0.05).  
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Figure 8: Plasma estrone concentrations in normotension and during the development 
of hypertension in intact female rats. Bars are means ± S.E. (n = number of rats). 
Samples were taken starting on the day of coarctation and on each day of diestrus 
thereafter. a-bWithin each group (INT-NT or INT-HT), mean values without common 
script are significantly different (0.0145 ≤ P ≤ 0.0329). *Denotes significant differences 
between NT and HT groups (INT-NT vs. INT-HT) at like time points (Time 1) (P ≤ 
0.0445). 
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Figure 9: Plasma estradiol concentrations in OVX-NT and OVX-HT female 
rats at coarctation or sham (day 0) and at days 4, 7 and 10 following 
coarctation. Bars are means ± S.E. (n = number of rats). a-bWithin OVX-NT 
group, mean values without a common script are significantly different 
(0.0003 ≤ P ≤ 0.001). Mean values in OVX-HT do not differ significantly (P 
> 0.05). * Denotes significant differences between NT and HT groups (OVX-
NT vs. OVX-HT), at like time points (days 0, 4 and 7) (0.0111 ≤ P ≤ 
0.0402).  
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Figure 10: Plasma estrone concentrations in OVX-NT and OVX-HT female 
rats at coarctation or sham (day 0) and at days 4, 7 and 10 following 
coarctation. Bars are means ± S.E. (n = number of rats).  There were no 
significant differences within OVX-NT, OVX-HT or between NT and HT 
groups (P > 0.05).  
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Figure 11: Plasma estradiol concentrations in OVX+ER-NT and OVX+ER-
HT female rats at coarctation or sham (day 0) and at days 4, 7 and 10 
following coarctation. Bars are means ± S.E. (n = number of rats).  a-cWithin 
each group (OVX+ER-NT or OVX+ER-HT), mean values without common 
script are significantly different (0.0048 ≤ P ≤ 0.048). *Denotes significant 
differences between NT and HT groups (OVX+ER-NT vs. OVX+ER-HT) at 
like time points (Days 0, 4 and 7) (0.0087 ≤ P ≤ 0.0116).  
In OVX+ER-NT, plasma concentrations of estradiol exhibited a steady decline 
from day 0 through day 10. There was a 47% decrease from day 0 to day 4 (248.4 ± 
36.42 pg/ml vs. 137.6 ± 20.57 pg/ml) and then subsequent declines of 36% and 25% for 
the remaining two time points (87.40 ± 14.31 pg/ml and 65.40 ± 13.85 pg/ml).  
The plasma concentrations of estradiol in OVX+ER decreased 44% from day 0 to 
day 4 during the development of hypertension (115.0 ± 15.09 pg/ml vs. 60.75 ± 12.48 
pg/ml), but then remained fairly stable throughout the remaining samples, although there 
was a 23% decline on day 10 (to 46.67 ± 11.32 pg/ml) (Fig. 11).   
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 In OVX+ER, plasma estrone levels remained fairly stable throughout the 
development of hypertension, unlike plasma estradiol, which declined over time. Plasma 
estrone remained higher in OVX+ER-NT than in OVX+ER-HT on days 4, 7 and 10 (Fig. 
12). There was a slight increase on day 4 in OVX+ER-HT (42.0 ± 7.0 pg/ml vs. 65.5 ± 
10.75 pg/ml).  
 
 
 
 
 
Figure 12: Plasma estrone concentrations in OVX+ER-NT and OVX+ER-
HT female rats at coarctation or sham (day 0) and at days 4, 7 and 10 
following coarctation. Bars are means ± S.E. (n = number of rats). a- bWithin 
each group (OVX+ER-NT or OVX+ER-HT) mean values without common 
script are significantly different (0.0106 ≤ P ≤ 0.05). *Denotes significant 
differences between NT and HT groups (ER-NT vs. ER-HT) at like time 
points (Day 4, 7 or 10) (0.0034 ≤ P ≤ 0.0147).   
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4.2 Effects of Aortic Coarctation-Induced Hypertension and Estrogen Receptor 
Agonists on Mean Arterial Pressure 
Blood pressures were measured starting on day 2 after coarctation (or sham) 
surgery and every other day through day 12. In NT (sham) groups (INT, OVX, 
OVX+PPT and OVX+DPN), BP averaged 125 ± 3 mmHg, 120 ± 1 mmHg, 118 ± 3 
mmHg and 124 ± 4 mmHg respectively on day 2,  and did not differ over time within 
groups (P > 0.05) or between groups at days 2 or 12 (P > 0.05). The only exception was 
in OVX+DPN rats at day 12 (132 ± 2 mmHg), which was significantly higher than 
OVX+PPT at day 12 (119 ± 2 mmHg) (P < 0.01) (Fig. 13A).  
Aortic coarctation increased blood pressure notably in all groups. In HT groups 
(INT, OVX, OVX+PPT and OVX+DPN), BP averaged 166 ± 3 mmHg, 150 ± 4 mmHg, 
151 ± 7 mmHg and 157 ± 5 mmHg, respectively, on day 2 and BP increased over time 
within groups in INT (183 ± 4 mmHg), OVX+PPT (180 ± 4 mmHg) and OVX+DPN 
(182 ±  4 mmHg) (0.0058 ≤ P ≤ 0.0238), but not in OVX (153 ± 3 mmHg) (P = 0.27). 
Among groups, BP was higher in INT than in OVX at day 2 (P = 0.0028) and higher in 
INT, OVX+PPT and OVX+DPN than in OVX at day 12 (0.0005 ≤ P ≤ 0.0048) (Fig. 
13B).  
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A. 
Figure 13: (A) Mean arterial blood pressures (MAP) of rats following sham 
coarctation (normotension, NT; A) or induction of aortic coarctation-induced 
hypertension (HT; B) at days 2 and 12.  
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B. 
 
Figure 13 continued: (B) Mean arterial blood pressures (MAP) of rats following
sham coarctation (normotension, NT; A) or induction of aortic coarctation-induced 
hypertension (HT; B) at days 2 and 12. Bars are means ± SE (n = number of rats). a-
cMean values within each group (NT or HT) without common script are significantly 
different (0.0058 ≤ P ≤ 0.0238). *Mean values between NT and HT in all groups 
(INT, OVX, OVX+PPT and OVX+DPN) exhibited significant increases in MAP (P < 
0.001). 
 
 
 
 
 
 
4.3 Effects of Aortic Coarctation and Estrogen Receptors Agonists on TXA2 and 
PGI2 Release from the Mesenteric Arterioles 
4.3.1 TXA2 
Basal release of TXA2 (as the stable metabolite TXB2) during normotension did 
not differ among the groups, except for OVX+PPT-NT (82 ± 13 pg/mg tissue/45 
minutes), which was about 2-fold higher than OVX+DPN-NT (40 ± 8 pg/mg tissue/45 
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minutes) (P < 0.05) (Fig. 14). The largest increase in response to VP stimulation (10-8M) 
in NT rats was observed in INT-NT (46 ± 15 vs. 182 ± 55 pg/mg tissue/45 minutes; P < 
0.05). Stimulation with VP in OVX-NT and OVX+PPT-NT did not produce a significant 
increase in the release of TXA2 (51 ± 23 vs. 137 ± 38 and 82 ± 13 vs. 116 ± 24 pg/mg 
tissue/45 minutes) (P > 0.05). Stimulation with VP produced a small but significant 
increase in the release of TXA2 in OVX+DPN-NT versus basal release (40 ± 8 vs. 79 ± 
14 pg/mg tissue/45 minutes; P < 0.05). Aortic coarctation produced a dramatic increase in 
the basal release of TXA2 from mesenteric arterioles in all groups (INT, P < 0.001; OVX, 
P < 0.01; OVX+PPT, P < 0.02; OVX+DPN, P < 0.01); however, basal release did not 
differ among HT groups. INT-HT (58% increase) and OVX+PPT-HT (55% increase) 
increased TXA2 release the most in response to VP stimulation during hypertension, 
while OVX-HT (36% increase) and OVX+DPN-HT (35% increase) groups exhibited 
smaller increases. Stimulation with VP caused significant increases in all HT groups 
except OVX-HT (P > 0.05) (Fig. 14).  
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Figure 14: Basal and vasopressin (VP)-stimulated release of TXA2 
(measured as the stable metabolite TXB2) from mesenteric arterioles in 
normotensive (NT) and aortic coarctation-induced hypertensive (HT) rats. 
Bars are means ± S.E. (n = number of animals). INT, intact females; OVX, 
ovariectomized females; PPT, OVX females treated with PPT; DPN, OVX 
females treated with DPN. a-cMean values within each group (NT or HT) 
without common script are significantly different (0.0008 ≤ P ≤ 0.0482). 
*+Denotes significant differences between groups (NT vs. HT) (0.0008 ≤ P ≤ 
0.0199).  
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4.3.2 PGI2 
Basal release of PGI2 (as the stable metabolite 6-keto-PGF1α) in INT (742 ± 147 
pg/mg tissue/45 minutes), OVX (689 ± 75 pg/mg tissue/45 minutes) and OVX+DPN 
(625 ± 141 pg/mg tissue/45 minutes) did not differ during normotension. Basal release of 
PGI2 during normotension was highest in OVX+PPT treated animals (1,577 ± 228 pg/mg 
tissue/45 minutes) than the other groups (P < 0.05) (Fig. 15). VP stimulation produced 
significant increases in PGI2 release in INT (2,897 ± 490 pg/mg tissue/45 minutes), OVX 
(1,451 ± 292 pg/mg tissue/45 minutes) and OVX+DPN (1,418 ± 256 pg/mg tissue/45 
minutes), but not in OVX+PPT-NT (2,312 ± 591 pg/mg tissue/45 minutes) (P > 0.10) 
(Fig. 15). Coarctation increased basal release of PGI2 in all groups, but basal release 
during HT did not differ among groups. INT-HT (7,969 ± 1,659 pg/mg tissue), 
OVX+PPT-HT (8,971 ± 1,238 pg/mg tissue) and OVX+DPN-HT (6,030 ± 1,454 pg/mg 
tissue) produced similar amounts of PGI2 in response to VP. OVX-HT (4776 ± 865 
pg/mg tissue) produced significantly less PGI2 in response to VP than the other groups 
(Fig. 15).  
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Figure 15: Basal and vasopressin (VP)-stimulated release of PGI2 (measured 
as the stable metabolite 6-keto-PGF1α) from mesenteric arterioles in 
normotensive (NT) and aortic coarctation-induced hypertensive (HT) rats. 
Bars are means ± S.E. (n = number of animals). INT, intact females; OVX, 
ovariectomized females; OVX+PPT, OVX females treated with PPT; 
OVX+DPN, OVX females treated with DPN. a-cMean values within each 
group (NT or HT) without common script are significantly different (0.0040 
≤ P ≤ 0.0498). *+Denotes significant differences between groups (NT vs. HT) 
(0.0008 ≤ P ≤ 0.0338).  
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4.4 Effects of Aortic Coarctation and Estrogen Receptor Agonists on the 
Mesenteric Arteriole Response to Arginine Vasopressin 
In NT rats, INT (9.97 ± 0.75 mN/mm) exhibited a maximal response to VP 
similar to those of OVX (8.63 ± 0.58 mN/mm) and OVX+DPN (9.93 ± 0.53 mN/mm). 
OVX+PPT treatment in NT rats increased reactivity to VP (12.96 ± 0.64 mN/mm) 
compared to INT, OVX and OVX+DPN treatments at both middle and maximal 
concentrations (0.0002 ≤ P ≤ 0.02). INT differed significantly from OVX and 
OVX+DPN at the middle dose only (0.0271 ≤ P ≤ 0.0294) (Figs. 16A, 17A). However, 
aortic coarctation abolished the maximal differences in reactivity to VP between INT 
(11.77 ± 1.40 mN/mm), OVX (10.14 ± 1.01 mN/mm), OVX+PPT (11.39 ± 1.08 
mN/mm), and OVX+DPN (11.34 ± 1.39 mN/mm) (P > 0.05) (Figs. 16B, 17B). 
Hypertension did not alter the contractile responses to VP significantly in any group 
compared to normotensive controls (P > 0.05) (Figs. 16B, 17B).  
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A. Normotensive Control
 
Figure 16: (A) Concentration-response curves for arginine vasopressin (VP) 
in endothelium-intact mesenteric arterioles from INT, OVX, OVX+PPT- and 
OVX-+DPN-treated normotensive-control (NT; A) and hypertensive (HT; B) 
Sprague-Dawley rats. Contractile force was normalized by vessel length. 
Data points represent means ± S.E. (n = number of animals). #Statistically 
significant differences exist in OVX+PPT-NT vs. OVX+DPN-NT, INT-NT 
and OVX-NT (0.0002 ≤ P ≤ 0.02) at both middle (1x10-10M) and maximal 
(1x10-8M) concentrations of VP. *Statistically significant differences exist in 
INT-NT vs. OVX-NT and OVX+DPN-NT at the middle concentrations only 
(1x10-10M) (0.0271 ≤ P ≤ 0.0294). No statistically significant differences 
exist between OVX+DPN-NT and OVX-NT (P > 0.05).  
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B. Coarctation-Induced Hypertension 
 
Figure 16 continued: (B) Concentration-response curves for arginine 
vasopressin (VP) in endothelium-intact mesenteric arterioles from INT, 
OVX, OVX+PPT- and OVX-+DPN-treated normotensive-control (NT) 
Sprague-Dawley rats. Contractile force was normalized by vessel length. 
Data points represent means ± S.E. (n = number of animals). No statistically 
significant differences exist between the curves (P > 0.05).  
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A. Normotensive Control
 
Figure 17: (A) Concentration-response curves for arginine vasopressin (VP) 
in endothelium-intact mesenteric arterioles from OVX-PPT- and OVX-DPN-
treated normotensive-control (NT; A) and aortic coarctation-induced 
hypertensive (HT; B) Sprague-Dawley rats. Data points represent means ± 
S.E. (n = number of animals). *Statistically significant differences exist in 
OVX+PPT-NT vs. OVX+DPN-NT (0.0001 ≤ P ≤ 0.004) at both middle 
(1x10-10M) and maximal (1x10-8M) concentrations of VP. 
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B. Coarctation-Induced Hypertension 
 
Figure 17 continued: (B) Concentration-response curves for arginine 
vasopressin (VP) in endothelium-intact mesenteric arterioles from 
OVX+PPT- and OVX+DPN-treated normotensive-control (NT; A) and 
aortic coarctation-induced hypertensive (HT; B) Sprague-Dawley rats. 
Contractile force was normalized by vessel length. Data points represent 
means ± S.E. (n = number of animals). No statistically significant differences 
exist between OVX+PPT-HT vs. OVX+DPN-HT (P > 0.05).  
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4.4.1 Effects of SQ 29,548 on the Vasopressin Concentration Response 
There were no significant differences in any of the groups in the presence of SQ 
29,548 (SQ) (P > 0.05) (Figs. 18 thru 25). 
 
 
Figure 18: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from INT-NT female Sprague-
Dawley rats in the presence of SQ 29,548 (SQ, 1 µM) or vehicle-control. 
Contractile force was normalized by vessel length. Data points are means ± 
S.E. (n = number of animals). There were no statistically significant 
differences in INT-NT for SQ vs. VEH (P > 0.05). 
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 Figure 19: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX-NT female Sprague-
Dawley rats in the presence of SQ 29,548 (SQ, 1 µM) or vehicle-control. 
Contractile force was normalized by vessel length. Data points are means ± 
S.E.; (n = number of animals). There were no statistically significant 
differences in OVX-NT for SQ vs. VEH (P > 0.05). 
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 Figure 20: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX+PPT-NT Sprague-
Dawley rats in the presence of SQ 29,548 (SQ, 1 µM) or vehicle-control. 
Contractile force was normalized by vessel length. Data points are means ± 
S.E. (n = number of animals). There were no statistically significant 
differences in OVX+PPT-NT for SQ vs. VEH (P > 0.05). 
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Figure 21: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX+DPN-NT Sprague-
Dawley rats in the presence of SQ 29,548 (SQ, 1 µM) or vehicle-control. 
Contractile force was normalized by vessel length. Data points are means ± 
S.E. (n = number of animals). There were no statistically significant 
differences in OVX+DPN-NT for SQ vs. VEH (P > 0.05). 
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Figure 22: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from INT-HT Sprague-Dawley rats 
in the presence of SQ 29,548 (SQ, 1 µM) or vehicle-control. Contractile 
force was normalized by vessel length. Data points are means ± S.E. (n = 
number of animals). There were no statistically significant differences in 
INT-HT for SQ vs. VEH (P > 0.05). 
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 Figure 23: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX-HT Sprague-Dawley rats 
in the presence of SQ 29,548 (SQ, 1 µM) or vehicle-control. Contractile 
force was normalized by vessel length. Data points are means ± S.E. (n, = 
number of animals). There were no statistically significant differences at 
either the middle or highest dose in OVX-HT for SQ vs. VEH (P > 0.05). 
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Figure 24: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX+PPT-treated HT 
Sprague-Dawley rats in the presence of SQ 29,548 (SQ, 1 µM) or vehicle-
control. Contractile force was normalized by vessel length. Data points are 
means ± S.E. (n = number of animals). There were no statistically significant 
differences in OVX+PPT-HT for SQ vs. VEH (P > 0.05). 
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 Figure 25: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX+DPN-treated HT 
Sprague-Dawley rats in the presence of SQ 29,548 (SQ, 1 µM) or vehicle-
control. Contractile force was normalized by vessel length. Data points are 
means ± S.E. (n = number of animals). There were no statistically significant 
differences in OVX+DPN-HT for SQ vs. VEH (P > 0.05). 
 
 
 
 
 
 
 
 
 
 
 Table 3. A. Maximal contractile responses to vasopressin (A) and sensitivity to VP (EC50; B) for vehicle-control and SQ 
29,548 treated mesenteric arterioles.
 INT-NT OVX-NT OVX+PPT- NT 
OVX+DPN-
NT INT-HT OVX-HT 
OVX+PPT-
HT 
OVX+DPN-
HT 
n 5 6 6 6 6 6 6 6 
Vehicle-
Control 
(mN/mm) 
9.97 ± 0.87b 8.63 ± 0.64b 12.96 ± 0.71a 9.93 ± 0.58b 11.77 ± 1.40 10.14 ± 1.01 11.39 ± 1.08 11.34 ± 1.39 
SQ 29,548 
(mN/mm) 9.16 ± 1.53
b 9.48 ± 1.14b 11.40 ± 1.76a,b 9.71 ± 0.82b 12.69 ± 1.77 8.43 ± 1.27 12.25 ± 0.85 9.56 ± 1.02 
         
           
 INT-NT OVX-NT OVX+PPT-NT 
OVX+DPN-
NT INT-HT OVX-HT 
OVX+PPT-
HT 
OVX+DPN-
HT 
n 5 6 6 6 6 6 6 6 
Vehicle-
Control 
(pM) 
6.19 x 10-12 
 ±  
1.49 x 10-12 
8.88 x 10-12 
 ±  
2.87 x 10-12 
14.8 x 10-12  
±  
2.39 x 10-12 
19.5 x 10-12 
 ±  
10.9 x 10-12 
15.5 x 10-12 
±  
8.04 x 10-12 
12.5 x 10-12 
±  
2.8 x 10-12 
8.62 x 10-12  
± 
3.23 x 10-12 
26.7 x 10-12  
±  
16.3 x 10-12 
SQ 29,548 
(pM) 
10.50 x 10-12  
±  
2.19 x 10-12 
15.7 x 10-12  
±  
7.02 x 10-12 
16.3 x 10-12 
 ± 
 3.47 x 10-12 
17.4 x 10-12 
 ± 
 5.31 x 10-12 
22.0 x 10-12 
± 
13.8 x 10-12 
20.1 x 10-12 
± 
12.0 x 10-12 
9.02 x 10-12 
 ±  
3.33 x 10-12 
54.1 x 10-12 
 ± 
28.9 x 10-12 
         
Table 3. B.  
Note: Values are means ± S.E. (n = number of rats). a-bMean values within normotensive (NT) without common script are 
significantly different (0.0002 ≤ P ≤ 0.02). There were no significant differences in EC50 between vehicle-control and SQ 
29,548 treated microvessels. 79
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4.4.2 Effects of Simvastatin on Mesenteric Arteriole Responses to Vasopressin  
Arterioles from INT-NT and OVX-NT rats were treated with 60 µM Simvastatin 
(SIM). At this concentration, SIM nearly eliminated contractile responses to VP 
throughout the concentration-response curve (maximal responses were 0.12 ± 0.03 
mN/mm and 0.11 ± 0.06 mN/mm respectively; 99% reduction from vehicle-control) 
(Table 4). Subsequently, the remaining six groups were treated with 10 µM SIM. 
Mesenteric arterioles in all groups exhibited significant attenuation (0.0001 ≤ P ≤ 0.05) of 
the contractile responses to VP throughout the range of concentrations in the presence of 
SIM. In OVX+PPT-NT, SIM reduced the contractile response to VP by 73% at the 
maximal concentration of VP (10-8M) (12.96 ± 0.64 mN/mm vs. 3.52 ± 0.65 mN/mm) 
(Fig. 26), whereas OVX+DPN-NT exhibited a 92% reduction at the maximal 
concentration of VP (9.93 ± 0.53 mN/mm vs. 0.78 ± 0.25 mN/mm) (Fig. 27).  
In INT-HT, SIM reduced the maximal response to VP by 35% (11.77 ± 1.40 
mN/mm vs. 7.62 ± 1.01 mN/mm respectively) (Fig. 28), while in OVX-HT the maximal 
response to VP was reduced by 61% (10.14 ± 1.01 mN/mm vs. 3.91 ± 0.45 mN/mm 
respectively) (Fig. 29). In PPT-HT, SIM reduced the maximal response to VP by 28% 
(11.39 ± 1.08 mN/mm vs. 8.15 ± 1.26 mN/mm respectively) (Fig. 30), while in DPN-HT, 
SIM reduced the maximal response to VP by 62% (11.34 ± 1.39 mN/mm vs. 4.35 ± 0.76 
mN/mm respectively) (Fig. 31).  In arterioles from both INT-NT and INT-HT rats, SIM 
had a profound effect to decrease sensitivity to VP. 
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Figure 26: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX+PPT-treated NT Sprague-
Dawley rats in the presence of Simvastatin (SIM, 10 µM) or vehicle-control. 
Contractile force was normalized by vessel length. Data points are means ± S.E. (n 
= number of animals). *Statistically significant differences exist in OVX+PPT-NT 
for SIM vs. VEH (P = 0.0001) at both middle (1x10-10M) and maximal (1x10-8M) 
concentrations of VP. 
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Figure 27: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX+DPN-treated NT Sprague-
Dawley rats in the presence of Simvastatin (SIM, 10 µM) or vehicle-control. 
Contractile force was normalized by vessel length. Data points means ± S.E. (n = 
number of animals). *Statistically significant differences exist in OVX+DPN-NT for 
SIM vs. VEH (0.001 ≤ P ≤ 0.0084) at both middle (1x10-10M) and maximal (1x10-
8M) concentrations of VP. 
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 Figure 28: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from INT-HT Sprague-Dawley rats 
in the presence of Simvastatin (SIM, 10 µM) or vehicle-control. Contractile 
force was normalized by vessel length. Data points are means ± S.E. (n = 
number of animals). *Statistically significant differences exist in INT-HT for 
SIM vs. VEH (0.0012 ≤ P ≤ 0.0319) at both middle (1x10-10M) and maximal 
(1x10-8M) concentrations of VP.  
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Figure 29: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX-HT Sprague-Dawley rats 
in the presence of Simvastatin (SIM, 10 µM) or vehicle-control. Contractile 
force was normalized by vessel length. Data points are means ± S.E. (n = 
number of animals). *Statistically significant differences exist in INT-HT for 
SIM vs. VEH (0.0002 ≤ P ≤ 0.0005) at both middle (1x10-10M) and maximal 
(1x10-8M) concentrations of VP.  
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Figure 30: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX-PPT-treated HT female 
Sprague-Dawley rats in the presence of Simvastatin (SIM, 10 µM) or vehicle-
control. Contractile force was normalized by vessel length. Data points 
represent means ± S.E. (n = number of animals). *Statistically significant 
differences exist in PPT-OVX-HT for SIM vs. Veh (0.0044 ≤ P ≤ 0.05) at both 
middle (1x10-10M) and maximal (1x10-8M) concentrations of VP.  
 
 
 
 
 
 
 
 
 
 
 
  
86
 
 
 Figure 31: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact mesenteric arterioles from OVX-DPN-treated HT female 
Sprague-Dawley rats in the presence of Simvastatin (SIM, 10 µM) or vehicle-
control. Contractile force was normalized by vessel length. Data points 
represent means ± S.E.; (n = number of animals). *Statistically significant 
differences exist in OVX-DPN-HT for SIM vs. VEH (0.0003 ≤ P ≤ 0.0019) at 
both middle (1x10-10M) and maximal (1x10-8M) concentrations of VP.  
 
 
 
 
 
 
 
 Table 4. A. Maximal contractile responses to vasopressin (A) and sensitivity to VP (EC50; B) for vehicle-control and simvastatin 
treated mesenteric arterioles. 
 INT-NT OVX-NT OVX+PPT-NT 
OVX+DPN-
NT INT-HT OVX-HT 
OVX+PPT-
HT 
OVX+DPN-
HT 
n 5 6 6 6 6 6 6 6 
Vehicle-
Control 
(mN/mm) 
9.97 ± 0.87b 8.63 ± 0.64b 12.96 ± 0.71a 9.93 ± 0.58b  11.77 ± 1.40a 10.14 ± 1.01a 11.39 ± 1.08a 11.34 ± 1.39a 
Simvastatin 
(mN/mm) 
0.12 ± 0.03c 
(60 µM) 
0.11 ± 0.07c 
(60 µM) 
3.52 ± 0.71d 
(10 µM) 
0.78 ± 0.31c 
(10 µM) 
7.62 ± 1.01c 
(10 µM) 
3.91 ± 0.45b 
(10 µM) 
8.15 ± 1.26c 
(10 µM) 
4.35 ± 0.76b 
(10 µM) 
         
 
 INT-NT OVX-NT OVX+PPT-NT 
OVX+DPN-
NT INT-HT OVX-HT 
OVX+PPT-
HT 
OVX+DPN-
HT 
n 5 6 6 6 6 6 6 6 
Vehicle-
Control 
(mN/mm) 
6.19 x 10-12 
 ±  
1.49 x 10-12b 
8.88 x 10-12 
 ±  
2.87 x 10-12ab 
14.8 x 10-12  
±  
2.39 x 10-12*a 
19.5 x 10-12 
 ±  
10.9 x 10-12*ab 
15.5 x 10-12  
±  
8.04 x 10-12* 
12.5 x 10-12  
±  
2.8 x 10-12* 
8.62 x 10-12  
± 
3.23 x 10-12* 
26.7 x 10-12  
±  
16.3 x 10-12* 
Simvastat
in 
(mN/mm) 
-- -- 
877.0 x 10-12 
 ± 
 213.0 x 10-12* 
1040.0 x 10-12 
 ± 
 405.0 x 10-12* 
684.0 x 10-12  
± 
81.1 x 10-12*a 
902.0 x 10-12 
 ± 
329.0 x 10-12*ab 
325.0 x 10-12 
 ±  
63.1 x 10-12*b 
644.0 x 10-12
 ± 
226.0 x 10-
12*ab 
         
Table 4. B.  
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Note: Values are means ± S.E. (n = number of rats). a-dMean values within normotensive (NT) or hypertensive (HT) maximum 
contraction without common script are significantly different (0.0002 ≤ P ≤ 0.05). *Mean values between vehicle control and 
simvastatin EC50 are significantly different (0.0001 ≤ P ≤ 0.0167). a-bMean values within normotensive (NT) or hypertensive 
(HT) EC50 without common script are significantly different (0.0048 ≤ P ≤ 0.0134). 
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4.5 Effect of Estrogen Receptor Agonists on Thoracic Aorta Responses to 
Vasopressin  
The contributions of the thromboxane pathway and intracellular calcium to VP-
induced contractions of the rat thoracic aorta were quite different than those in the 
mesenteric arteriole. In OVX+PPT-NT (3,887 ± 247 mg/mg ring wt.), SQ attenuated the 
contractile response to VP by 34% (2,577 ± 173 mg/mg ring wt.), while in OVX+DPN-NT 
(3,038 ± 472 mg/mg ring wt.), SQ attenuated the contractile response to VP by 56% (1,328 
± 167 mg/mg ring wt.).  In OVX+PPT-NT, SIM (60 µM) attenuated the contractile 
response to VP by 34%, (2,572 ± 274 mg/mg ring wt.), while in OVX+DPN-NT SIM 
attenuated the contractile response to VP by only 18% (2,497 ± 164 mg/mg ring wt.) (Figs. 
32 and 33).  
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Figure 32: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact aortic ring segments from OVX+PPT-treated NT Sprague-Dawley 
rats in the presence of Simvastatin (SIM, 60 µM), SQ 29,548 (SQ, 1 µM) or vehicle-
control. Contractile force was normalized by dry ring weight. Data points are means ± 
S.E. (n = number of animals). *Statistically significant differences exist in OVX-PPT-
NT for SQ and SIM vs. vehicle-control (0.0025 ≤ P ≤ 0.0220) at both middle (1x10-
8M) and maximal (1x10-6 M) concentrations of VP.  
 
 
  
 
 
 
 
 
 
 90
 
Figure 33: Concentration-response curves for arginine vasopressin (VP) in 
endothelium-intact aortic ring segments from OVX+DPN-treated NT Sprague-
Dawley rats in the presence of Simvastatin (SIM, 60 µM), SQ 29,548 (SQ, 1 µM) or 
vehicle-control. Contractile force was normalized by dry ring weight. Data points 
are means ± S.E. (n = number of animals). *Statistically significant differences exist 
in OVX-DPN-NT for SQ vs. vehicle-control (0.0055 ≤ P ≤ 0.0208) at both middle 
(1x10-8M) and maximal (1x10-6 M) concentrations of VP.  
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4.6 Effect of Aortic Coarctation-Induced Hypertension and Estrogen Treatment 
on Estrogen Receptor Expression 
 
4.6.1 Real Time RT-PCR 
Neither estrogen replacement nor aortic coarctation caused significant changes in 
the expression of ERα or ERβ (P > 0.05) (Figs. 34, 35).  
 
 
A. Log 10 Scale 
 Figure 34: (A) Effect of hypertension and estrogen receptor agonists on 
mRNA levels of estrogen receptor alpha. ERα was quantified by the ΔCT 
method and expressed relative to ERα of INT-NT in both log 10 scale 
(A) and linear scale (B). Bars are means ± SE. (n = number of animals). 
There were no significant differences in ERα mRNA levels (P > 0.05). 
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B. Linear Scale 
 
 
 
Figure 34 continued: (B) Effect of hypertension and estrogen receptor 
agonists on mRNA levels of estrogen receptor alpha. ERα was quantified 
by the ΔCT method and expressed relative to ERα of INT-NT in both log 
10 scale (A) and linear scale (B). Bars are means ± SE. (n = number of 
animals). There were no significant differences in ERα mRNA levels (P 
> 0.05). 
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A. Log 10 Scale 
 Figure 35: (A) Effect of hypertension and estrogen receptor agonists 
on mRNA levels of estrogen receptor beta. ERβ was by the ΔCT 
method and expressed relative to ERβ of INT-NT in both log 10 scale 
(A) and linear scale (B). Bars are means ± SE. (n = number of 
animals). There were no significant differences in ERβ mRNA levels 
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B. Linear Scale 
 Figure 35 continued: (B) Effect of hypertension and estrogen 
receptor agonists on mRNA levels of estrogen receptor beta. ERβ was 
by the ΔCT method and expressed relative to ERβ of INT-NT in both 
log 10 scale (A) and linear scale (B). Bars are means ± SE. (n = 
number of animals). There were no significant differences in ERβ 
 
 
 
 
4.6.2 Immunoblots 
Neither estrogen receptor agonist treatment nor aortic coarctation caused significant 
changes in the protein expression of ERα or ERβ (P > 0.05) (Figs. 36, 37).  
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Figure 36: Effect of hypertension and estrogen receptor agonists on 
the expression of estrogen receptor alpha. ERα was quantified by 
densitometry analysis, normalized to beta actin and expressed relative 
to ERα of INT-NT density. Bars are means ± SE. (n = number of 
animals). There were no significant differences in ERα protein 
expression (P > 0.05). 
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Figure 37: Effect of hypertension and estrogen receptor agonists on the 
expression of estrogen receptor beta. ERβ was quantified by 
densitometry analysis, normalized to beta actin and expressed relative to 
ERβ of INT-NT density. Bars are means ± SE. (n = number of animals). 
There were no significant differences in ERβ protein expression (P > 
0.05). 
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 OVX HT OVX+ER-HT 
 
 
 
ERβ 56 kD 
+ Control 
INT NT INT HT OVX NT OVX+ER-NT 
ERα 67 kD 
+ Control 
INT HT INT NT OVX HT OVX NT 
 
 
Beta actin 42 kD 
+ Control 
 OVX+PPT-NT OVX+PPT-HT OVX+DPN-NT OVX+DPN-HT 
 Figure 38: Representative immunoblot analysis of ERα, ERβ and beta actin 
(loading control) in mesenteric arterioles.  
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CHAPTER V 
SUMMARY AND DISCUSSION 
 
This study investigated the effects of estrogen and selective estrogen receptor 
agonists on the regulation of mean arterial blood pressure and prostanoid function and on 
the roles of thromboxane and intracellular calcium in vascular reactivity of mesenteric 
arterioles to vasopressin in the female Sprague-Dawley rat. The central hypothesis tested 
was that in aortic coarctation-induced hypertension, estrogen upregulates the constrictor 
prostanoid pathway in the vascular wall via activation of ERβ, enhancing vascular tone and 
leading to deleterious effects on blood pressure in the female rat. If so, then rats treated 
with an ERβ agonist would have higher mean arterial pressures than rats treated with an 
ERα agonist, as well as increased release of constrictor prostanoids from the vasculature, 
which would potentiate vascular reactivity to VP. ERβ was suspected of having a main 
role, based on evidence that it is the more abundant vascular ER.  Indeed, rats treated with 
DPN (ERβ agonist) exhibited mean arterial pressures comparable to those of intact female 
rats during the development of aortic coarctation-induced hypertension. However, PPT- 
(ERα agonist) treated rats exhibited similar mean arterial pressures as those seen with DPN 
treatment. While both treatments resulted in similar increases in blood pressure during 
aortic coarctation-induced hypertension, which were greater than those in OVX rats, there 
were significant differences in the release of constrictor prostanoids from the mesenteric 
vasculature in both normotension and hypertension in ERα vs. ERβ-treated rats. During the 
development of hypertension, mean arterial pressures in PPT-treated rats can be explained 
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by the increase in thromboxane release by the mesenteric vascular wall in this group, while 
the DPN-treated group appears to have another mechanism mediating increases in blood 
pressure during aortic coarctation-induced hypertension. Prostacyclin release exhibited 
similar trends as thromboxane, but with a few minor differences.  
In mesenteric vascular function studies, blocking the thromboxane receptor with 
SQ 29,548 did not affect the contractile responses to VP in any groups. However, blocking 
intracellular calcium release from the sarcoplasmic reticulum with SIM resulted in 
differential effects in both normotensive and hypertensive groups and among INT, OVX, 
PPT and DPN groups. SIM had a greater effect in normotensive than in hypertensive rats, 
and a greater effect in DPN-treated groups than in PPT-treated groups, even during 
hypertension. The vascular function studies performed in the mesenteric arterioles did not 
mirror preliminary studies performed in the aorta, where SQ 29,548 treatment attenuated 
contractile responses to VP to differing extents in normotensive PPT and DPN treated rats, 
and SIM appeared to have greater effects in the PPT-treated group rather than the DPN-
treated group. These studies may reflect regional differences in the roles of ERα and ERβ 
and/or intracellular Ca2+ handling in aorta vs. mesentery. 
In most experiments in this study, PPT treatment closely mimicked function in INT 
rats, while DPN treatment more closely resembled function in OVX rats. This would 
suggest that most of the actions of estrogen on constrictor prostanoid function and vascular 
reactivity to VP are mediated by ERα alone. A noticeable instance where DPN treatment 
had similar results to INT was in the development of ACIH, where MAP was just as severe 
in the DPN treated group at 12 days as in INT and PPT-treated rats.   
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5.1 Effects of Aortic Coarctation-Induced Hypertension on Plasma Estradiol and 
Estrone Levels 
In the present studies, plasma levels of 17β-estradiol and estrone were measured in 
normotensive and ACIH rats in an effort to determine whether the development of ACIH 
was associated with alterations in the secretion and/or metabolism of estrogens. Studies in 
humans with essential hypertension revealed that serum levels of estradiol were higher in 
both men and women (59, 65) compared to their normotensive counterparts. In the present 
study, estradiol levels in INT-HT females were not altered; however, OVX-HT females 
had slight but significant increases in plasma estradiol on days 0, 4 and 7 post-coarctation, 
indicating an increase from an extra-ovarian source of estradiol, most likely the adrenal 
gland. In OVX+ER-HT, plasma estradiol on days 0, 4 and 7 post-coarctation were 
significantly lower than in OVX+ER-NT. Although the estradiol level at day 0 in 
OVX+ER-NT was twice that of OVX+ER-HT (the pellets from the NT group had a higher 
rate of E2 release than is normally expected), the rate of estrogen metabolism appeared to 
differ between the two groups. OVX+ER-NT had a steady rate of decline from day 0 to 
day 4 to day 7, with no significant decrease between day 7 and day 10. In contrast, 
OVX+ER-HT had a significant decline from day 0 to day 4, but the levels were steady 
from day 4 to days 7 and 10. This suggests that during ACIH, exogenous estrogen is 
metabolized at a faster rate than during NT, while ovarian estrogen secretion does not 
change during ACIH.  
In the present study, plasma estrone levels in INT and OVX females were very 
similar, both in normotension and during the development of ACIH. This suggests that the 
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production of estrone is independent of ovarian function, and likely arises from peripheral 
conversion of adrenal derived E2. The levels of estrone in the present study in INT rats 
were similar to those in a previous study (121). In the present study, the presence of the 
exogenous estrogen source in OVX+ER groups resulted in higher levels of estrone, due to 
the conversion of 17β-estradiol to estrone by 17β-hydroxysteroid dehydrogenase in the 
periphery. 
One interesting observation of the present study was the trend of estrone to closely 
follow 17β-estradiol, indicating that, for the most part, where 17β-estradiol increased or 
decreased, estrone also exhibited parallel increases or decreases. This serves as an internal 
control and verifies that the changes in estrogen levels measured by RIA are authentic. 
 
5.2 Effects of Aortic Coarctation-Induced Hypertension and Estrogen Receptor 
Agonists on Mean Arterial Pressure 
The present study revealed that INT-HT rats exhibited a higher MAP at day 2 than 
OVX-HT or OVX+PPT-HT, while MAP of OVX+DPN-HT did not differ from INT-HT 
on day 2. However by 12 days post-coarctation, the differences among INT, OVX+ER-
agonist and OVX treated groups had progressively widened to reveal marked statistically 
significant differences in MAP. At 12 days post-coarctation, MAP during treatment with 
either ERα or ERβ agonists closely resembled that of INT rats while OVX rats exhibited a 
significantly lower MAP.  
These results support previous work by Baltzer et al. (6, 7)  which reported that the 
presence of estrogen in INT or OVX+ER rats results in a higher MAP than in OVX or 
male rats at days 12-14 of ACIH (6, 7, 8). One difference between this and the present 
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study is the significantly higher MAP at day 2 in INT-HT rats when compared to OVX-HT 
rats in this study. Prior to the studies by Baltzer et al. (6, 7, 8), there were only two short-
term investigations that examined MAP in female rats with ACIH. One study revealed that 
chronic estradiol treatment increased the sensitivity of the carotid arteries to ANG II 
induced-vasoconstriction (116), while another study compared the effects of partial aortic 
coarctation in pregnant vs. virgin female rats and found that in pregnant females there was 
an increase in MAP (54). While the Henzel study did not find any change in the MAP of 
virgin female rats, this is most likely due to the use of partial aortic coarctation, rather than 
the complete aortic coarctation that was used in the present study as well as the Baltzer 
study (6, 7, 8).  
While there were subtle differences in MAP between INT-HT, OVX+PPT-HT and 
OVX+DPN-HT at day 2, these differences were abolished at day 12. The higher MAP of 
OVX+DPN-HT rats at day 12 is likely due to a different mechanism (perhaps neural 
mechanisms involved in ACIH) than that of INT-HT and OVX+PPT-HT rats, as 
mesenteric arteriolar TXA2 production in response to VP-stimulation was nearly half that 
of OVX+PPT-HT, but not significantly different than arterioles from INT-HT rats. 
Previous studies by Baltzer et al. (6, 7, 8) revealed that acute infusion of SQ 29,548 (TP 
receptor antagonist) at day 14 or chronic treatment with Ridogrel (TP receptor 
antagonist/TXS inhibitor) during the development of ACIH during days 1-14 significantly 
attenuated the MAP of INT and OVX+ER females at 12-14 days to a much greater extent 
than in OVX or male rats, indicating that TXA2 and TP receptor activation are central to 
the effects of estrogen to exacerbate MAP in ACIH. In the present study, increased 
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arteriolar TXA2 production in OVX+PPT-HT and INT-HT rats can be associated with the 
high MAP observed at day 12, based on the findings in the present studies and those of 
Baltzer et al. (6, 7, 8) involving systemic administration of SQ, which lowered MAP 
markedly in INT-HT rats. However, the high MAP observed in OVX+DPN-HT cannot be 
explained by a massive increase in TXA2, since the arterioles from this group did not have 
similar increases in TXA2 production when stimulated with VP.  
A previous study examined blood pressure and vascular function in male ERβ 
knock-out mice and found that the absence of ERβ resulted in systolic and diastolic 
hypertension with aging, suggesting that ERα, when unopposed by ERβ, possesses the 
ability to exert detrimental effects on blood pressure (152). In the present study, both 
selective and non-selective ER agonist activity clearly exacerbate the development of 
ACIH. Based on the data in the present study, there is no difference at day 12 in MAP 
whether PPT (ERα), DPN (ERβ) or 17β-estradiol (ERα and ERβ) are present. It is apparent 
that the activity of both of the ERs is detrimental and exacerbates MAP in ACIH.  
Based on previous studies of the effects of 17β-estradiol to upregulate TXA2 
production in the vascular wall, as well as TxS and TP receptors (73), and studies 
demonstrating that females rely more on intracellular calcium release in the contractile 
response to VP (36), the mechanisms by which ERα and ERβ modulate blood pressure 
may lie in differences in these two pathways (see sections 5.3.1 and 5.3.2).  
 
 
 
 104
5.3 Effects of Aortic Coarctation and Estrogen Receptor Agonists on TXA2 and 
PGI2 Release from the Mesenteric Vasculature 
In the present study, basal release of PGI2 and TXA2 was similar across all NT 
groups; however, OVX+PPT treatment resulted in a higher basal release of TXA2 than 
OVX+DPN treatment. Similarly, basal release of PGI2 also was higher in OVX+PPT than 
in all other groups. The effect of OVX+PPT to increase both TXA2 and PGI2 release in 
arterioles from normotensive rats suggests that a common precursor is upregulated by PPT, 
possibly COX-2. Recent studies by Li et al. (73) support this idea, since 17β-estradiol 
replacement therapy upregulated expression of both COX-2 and TxS, enhancing the 
release of both TXA2 and PGI2 in the NT female rat aorta (73). Other studies have 
demonstrated that estrogen treatment increases COX-2 protein in cultured endothelial cells 
(2, 131). 
Likewise, the dramatic increase in basal release of both TXA2 and PGI2 across all 
the groups during the development of ACIH in the present study demonstrates that a 
precursor molecule common to both TXA2 and PGI2 is upregulated during hypertension, 
likely COX-1 or COX-2, and possibly both. Previous studies have shown that 
prostaglandin release is increased during hypertension (7, 74, 75) and that 17β-estradiol 
upregulates the prostaglandin pathway, from COX-2 to TxS to the TP receptor (73). 
Therefore, there is a synergistic effect of hypertension and the presence of estrogen to 
increase prostaglandin production and activity. However, the effects of specific ER 
agonists demonstrated that significant differences exist in the extent to which ERs can 
affect TXA2 and PGI2 production during the development of ACIH. 
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5.3.1 TXA2 
The present study quantified basal and VP-stimulated TXA2 release from 
mesenteric arterioles in normotension and during the development of ACIH hypertension. 
In normotensive rats, basal release did not differ among the groups with the exception of 
OVX+PPT arterioles, which exhibited higher basal release of TXA2 than OVX+DPN 
treatment. For INT and OVX groups, this consistency in basal release is in agreement with 
previous studies of the female rat aorta, where basal release did not differ between INT, 
OVX and OVX+ER females (73).  
In the present study, arterioles from INT-NT rats demonstrated the largest increase 
in TXA2 release of all NT groups in response to VP-stimulation. While arterioles from 
OVX and OVX+DPN rats also exhibited significant increases in TXA2 release in response 
to VP, agonist-induced increases were much smaller than in INT rats. In OVX+PPT rats, 
VP-induced release of TXA2 did not differ significantly from basal release.  
During the development of hypertension, basal release among groups did not differ 
from one another, although ACIH increased basal release of TXA2 in all of the groups 
compared to NT rats. Arterioles from INT, OVX+PPT and OVX+DPN groups all 
exhibited higher agonist-induced release of TXA2 compared to OVX. While the statistical 
analysis did not detect any significant differences in VP-stimulated TXA2 release between 
OVX+DPN-HT and OVX+PPT-HT, this is likely due to the small sample size of the 
OVX+DPN-HT group (n = 3), because the mean difference in TXA2 production by 
OVX+PPT-HT arterioles was nearly two-fold higher than that of OVX+DPN-HT vessels, 
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suggesting that this difference is likely to be biologically significant, based upon previous 
functional and prostanoid release studies in the rat aorta (72, 73). 
During the development of ACIH, TXA2 release appears to be reduced about half 
in the combined presence of both ERα and ERβ activity in the INT group, when compared 
to ERα activity alone in the PPT-treated group, where TXA2 production is quite high. This 
suggests that ERβ may have some inhibitory effects on ERα activities, which has been 
suggested by several previous studies on the interactions of ERs (28, 80, 81, 95, 130). It is 
possible that homodimer formation of ERα leads to the detrimental effects seen in the PPT-
treated group, since it appears that ERβ exerts any inhibitory effects on ERα through the 
preferential formation of heterodimers (80, 96). This formation of the homodimers alone in 
the PPT-treated group combined with ACIH may result in the significantly increased 
production of TXA2 and PGI2 seen in this study.  
 
5.3.2 PGI2 
In NT rats, basal release of PGI2 by arterioles from OVX+PPT rats was 2-2.5 fold 
higher than that of arterioles from INT, OVX+DPN or OVX rats. INT, OVX+DPN and 
OVX groups all exhibited significant increases in PGI2 release in response to VP, while 
arterioles from OVX+PPT rats did not. In HT rats, differences in basal release among the 
groups were abolished, although ACIH caused significant increases (2-3 fold) in the basal 
release of PGI2 in all the groups compared to NT rats. Arterioles from OVX+PPT-HT and 
INT-HT rats exhibited the highest VP-stimulated release of PGI2 overall, and significantly 
higher release than OVX-HT rats, while OVX+DPN-HT treatment did not differ from 
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OVX-HT. The differences observed between INT-HT and OVX-HT groups were expected, 
as 17β-estradiol is known to increase PGIS and PGI2 production (37, 98, 99, 114) as well 
as COX-2 and the production of PGI2 (73). While the evidence that estrogen upregulates 
COX-1, COX-2 and PGIS expression and PGI2 production is seemingly abundant in the 
literature, more often than not, these studies have failed to measure the effects of estrogen 
on TxS expression and TXA2 production. Based on the findings of the present study, it is 
clear that both pathways are upregulated not only by estrogen, but by any activity of the 
ERs, especially ERα.  
The findings of the present study suggest that ERα possesses the ability to 
upregulate PGIS as well as TxS, and likely the COX enzymes, while ERβ appears to have 
very little effect on TxS and the COX enzymes, but may act more on PGIS, at least during 
ACIH. Further, the present study suggests that the differential changes in basal and VP-
stimulated release of TXA2 and PGI2 in the presence of OVX+PPT vs. OVX+DPN vs. INT 
could result from the formation of hetero- or homodimers by the ERs, which could play a 
role in determining the physiological response or pathways that are influenced by estrogen.  
While TXA2 production is greatly increased during ACIH, PGI2 is increased to a 
much greater extent, raising the question of why PGI2 does not appear to provide a 
protective effect on blood pressure or vascular reactivity. The answer may reside in the 
chronic effects of TXA2 on the vasculature. While TXA2 acutely promotes platelet 
aggregation and powerful vasoconstriction (greater than that of angiotensin II), its long-
term effects include VSM hypertrophy and abnormal remodeling of the vascular wall (15, 
52). On the other hand, PGI2 works to combat these effects, by exerting anti-aggregatory 
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effects on platelets and inhibiting VSM hypertrophy (22, 24). These findings reveal that a 
delicate balance must be maintained between these two molecules in order for vascular 
homeostasis to prevail. Therefore, in the case of ACIH, this balance is severely disrupted, 
and the increased biological activity of TXA2 is unable to be overridden by the possible 
protective effects of PGI2, resulting in enhanced vascular reactivity to VP, thrombosis and 
MAP, especially in female rats.  
 
5.4 Effects of Aortic Coarctation and Estrogen Receptor Agonists on the 
Mesenteric Vascular Responses to Arginine Vasopressin 
The present study demonstrated clear differential effects of chronic treatment with 
selective ER agonists on mesenteric vascular function. In normotension, OVX+PPT 
treatment resulted in markedly higher contractile responses to VP compared to 
OVX+DPN, INT or OVX. These differences were abolished during ACIH, but the 
contractile force developed in mesenteric arterioles from ACIH groups were not 
significantly higher than that from NT rats, and in fact, OVX+PPT-HT developed slightly 
less contractile force than OVX+PPT-NT. At the middle concentrations only, VP produced 
significantly higher contractions in INT than in OVX or OVX+DPN. This result was 
expected in the INT and OVX groups, based on previous findings by Stallone et al. (72, 
126, 127, 128), which established that intact and estrogen-replaced females exhibit higher 
responsiveness to VP compared to males or OVX females, both in the aorta and the 
isolated perfused mesenteric vasculature.  
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A previous study of the effects of estrogen replacement on mesenteric arteriolar 
reactivity to VP found no differences between INT, OVX and OVX+ER rats (150). One 
possible reason for the differences between that study and the present study is the use of 
pressurized mesenteric vessels in the previous study, which were normalized to a maximal 
constriction to 120 mM KCl. While this is an acceptable format for reporting this type of 
data, normalizing the vessels in this manner can mask differences in maximal force 
developed by the different groups, and so it is difficult to determine whether there were 
any true differences in the maximal contractile responses to the vasoconstrictors. Further, 
the rats in this previous study were likely fed standard laboratory rat chow (it was not 
discussed in the paper), which is known to contain phytoestrogens (119, 120), which 
confound the effects of ovariectomy on vascular reactivity to VP (43, 72). The present 
study used an alfalfa- and soy-free diet, which is free of phytoestrogens.  
The increased responsiveness to VP in OVX+PPT-NT rats compared to INT-NT 
and OVX+DPN-NT in the present study was unexpected, since VP-stimulated release of 
TXA2 is not different between INT-NT, OVX+PPT-NT and OVX-DPN-NT groups, and 
therefore it is reasonable to assume that TXA2 production is not the only pathway 
differentially regulated by ERα and ERβ in the response to VP. In fact, this idea is 
supported by two previous studies, one involving sexual dimorphism and vascular 
reactivity to phenylephrine (PE) in rat aorta, which demonstrated that the female rat aorta 
was more reactive to PE than male aorta (43), and another demonstrating that estrogen 
augmented vasoconstriction to PE in male ERβ knock-out mice (152).  
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The present study also examined the role of ERα and ERβ in the mesenteric arterial 
response to VP during ACIH. While there were differences in the maximal response to VP 
in normotensive rats, these differences were abolished in hypertensive rats. While INT-HT, 
OVX+PPT-HT and OVX+DPN-HT developed slightly higher contractile force than OVX-
HT, due to the inherent animal to animal variability of the mesenteric arteriolar response to 
VP, they were not significantly different. However, the significantly lower MAP in OVX-
HT compared to the other ACIH groups would suggest that responses to constrictors 
should be blunted when compared to those of the ER treated groups. That they were not 
different may be due to the possible interactions between TXA2 and PGI2, as suggested by 
the effects of TP receptor blockade with SQ 29,548 (see next section).  
The fact that OVX+DPN-HT developed nearly identical contractile force as 
OVX+PPT-HT was unexpected. Although the TXA2 release in these two groups was not 
statistically different, the mean TXA2 production was 2-fold higher in OVX+PPT-HT, and 
this difference likely has biological relevance. The 2-fold difference in TXA2 production of 
these two groups would suggest that OVX+PPT-HT would possess greater reactivity to 
VP, as in the NT groups. However, the mechanism for the contractile responses of 
OVX+DPN-HT to VP remains unknown at this time. Further investigation into this 
mechanism is warranted.  
 
 
 
 
 
 111
5.4.1 Effects of SQ 29,548 on Concentration-Responses to Vasopressin 
To determine the role of ERs on TXA2 production and TP receptor function in the 
mesenteric vascular reactivity to VP in the present studies, the TP receptor antagonist SQ 
29,548 was employed in vascular function studies. INT-NT, OVX-NT, OVX+DPN-NT, 
OVX+DPN-HT, INT-HT and OVX+PPT-HT groups all produced significant amounts of 
thromboxane in response to VP, and yet SQ 29,548 did not have a significant effect on the 
contractile responses to VP (10-12 M – 10-8 M) (Figs. 18-25).   
In contrast, studies by Fulton et al. (43) demonstrated that contractile responses of 
the female rat aorta to VP were significantly higher in females than in males and that non-
selective inhibition of COX enzymes with Indo reduced contractile responses of female 
aorta to the same extent as SQ 29,548, suggesting that TXA2 and/or TP receptor activation 
were responsible for about 30% of VP-mediated contractions of the female rat aorta (43). 
Studies by Li et al. (72) further supported this idea, showing that the maximal response to 
TXA2 receptor analog U-46619 was significantly higher in female than in male rats, and 
that the maximal response in OVX rats was attenuated when compared to INT rats and that 
OVX+ER restored the contractile responses to U-46619 (72). Studies by Baltzer et al. (7) 
provided further in vivo support of this idea, since in ACIH, intravenous infusion of SQ 
during the acute phase of the hypertension (on day 12-14) in conscious rats resulted in a 
significantly greater decrease in MAP in INT female and OVX+ER female rats, compared 
to OVX or male rats. These findings consistently indicate that the TXA2 pathway is 
important in the regulation of arterial tone, which is responsible for controlling blood 
pressure. One earlier study found that OVX increased the sensitivity and maximal 
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contractility of mesenteric arterioles exposed to U-46619 when compared to OVX+ER 
(150); however, the vessels used in that study were endothelium-denuded, whereas those in 
the Fulton and Li studies (43, 72) and the present study were all endothelium intact vessels. 
Therefore, based upon the previous findings from the studies of Fulton, Li and Baltzer (6-
8, 43, 72, 73), a significant effect of SQ 29,548 to attenuate the contractile responses to VP 
was expected in the vascular function portion of the present study. The failure of TP 
receptor blockade to attenuate contractile responses to VP suggests that either the estrogen-
TXA2 mechanism is absent from the mesenteric vasculature, or that other local vasoactive 
factors may be masking the actions of TXA2.  
Indeed, more recent studies have suggested the possibility that other 
prostaglandins, especially PGI2, which is normally believed to be vasodilatory, may also 
contribute to vasoconstrictor responses of VSM to VP. In the Spontaneously Hypertensive 
Rat (SHR) aorta, the vasodilator agonist acetylcholine (ACh) induces contractile responses 
via agonist-induced release of a local vasoconstrictor factor (49, 107, 133). The Rapoport 
study (107) found that ACh-induced contractions of SHR and Wistar-Kyoto 
(normotensive) rat aortas are composed of two components: activation of the TP receptor, 
and activation of an additional PG receptor or receptors. That study determined that the 
amount of PGI2 produced by the aorta in response to ACh stimulation likely resulted in 
local concentrations of PGI2 in the micromolar range, and based on functional studies with 
carbacyclin (a PGI2 analogue), this concentration of PGI2 would be high enough to elicit 
the contractile responses observed in the aorta. Rapoport et al. (107) proposed that PGI2 
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was causing the constrictions through activation of the prostaglandin E (EP) receptor, since 
the constriction with carbacyclin occurred in the presence of SQ 29,548. 
Similarly, in the present study, the levels of PGI2 produced by the mesenteric 
arterioles in response to VP were 1.6 to 1.8 times higher than those in the Rapoport study. 
In fact, the groups with the highest output of PGI2, INT-HT and OVX+PPT-HT, actually 
demonstrated slightly higher contraction to VP in the presence of SQ (although not 
statistically significant). The abundance of PGI2 released by the mesenteric arterioles may 
mask the inhibitory effect of SQ 29,548 on TXA2-enhanced contraction via the TP 
receptor. If the PGI2 produced in response to VP stimulation is adequate to stimulate an EP 
receptor (likely EP3, as this receptor subtype is associated with contraction of vascular 
smooth muscle) (105), then this may mask the effects of SQ 29,548 to block effects of 
TXA2 in the contractile response to VP. The PGI2 contractile theory seems a likely 
candidate, given the amounts of TXA2 produced by the mesenteric arterioles in response to 
VP stimulation (especially during ACIH), as well as the substantially higher amounts of 
PGI2 being produced simultaneously by these arterioles. That production of these two 
prostanoids is upregulated in parallel suggests that several points along the AA metabolism 
pathway are upregulated, mainly COX-2, as well as PGIS and TxS.  
 
5.4.2 Effects of Simvastatin on the Vasopressin Concentration Dose Response 
To determine the role of ERs on intracellular calcium release by the sarcoplasmic 
reticulum in the mesenteric vascular response to VP, simvastatin (blocker of IP3 mediated 
IC release) (38, 94) was employed in the functional studies.  
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In the present studies, SIM significantly reduced the response to VP in all groups. 
The response was greater in NT than in HT, and greater in OVX+DPN and OVX than in 
INT and OVX+PPT. The greater dependence on IC release in the normotensive groups 
suggests that during hypertension there are other mechanisms contributing to the 
contractile response to VP, or that extracellular Ca2+ entry contributes more to contraction 
during ACIH. Another possibility is that blockade by SIM during ACIH is not as effective, 
due to greater contribution by intracellular calcium in contractile responses. Indeed, a 
previous study demonstrated that hypertensive rats exhibited a calcium dependent basal 
tone during ACIH, and that this tone was dependent upon TP receptor and COX (33). 
A previous study by Eatman et al. (36) demonstrated that a clear sexual 
dimorphism exists in the role of intracellular vs. extracellular calcium in the vascular 
reactivity to VP in the rat aorta, revealing that female rats were more dependent on IC 
release for VP-induced contraction, whereas male rats were more dependent upon 
extracellular calcium influx. In the present study, the observed differences between INT 
and OVX rats were not expected, as OVX resulted in greater dependence on IC release for 
VP-induced contraction. The change in calcium contribution with OVX demonstrates that 
in the absence of estrogens, the mechanisms of vascular function are altered and this might 
be central to understanding why post-menopausal women are more susceptible to 
cardiovascular disease. Although OVX did not produce the expected response, it is another 
example of how function of PPT-treated rats closely resembles function of INT rats while 
the function of DPN-treated rats resembles function of OVX rats, suggesting that ERα 
alone is capable of mediating the effects of estrogen on IC release. Previous studies have 
 
 115
shown the effects of 17β-estradiol to relax VSM by reducing IC concentration, either by 
increasing efflux or reducing influx via inhibition of L-type Ca2+ channels (50, 93, 104, 
113, 124). While it appears evident that estrogen receptors exert effects on Ca2+ in the 
vasculature, it remains unclear at this stage exactly what those effects are in differing 
tissues, as well as the differences in acute and chronic treatments. 
 
5.5 Effect of Estrogen Receptor Agonists on the Concentration-Response to 
Vasopressin in Rat Aorta 
In the present study, preliminary aortic function studies demonstrated clear 
differences in the effects of OVX+PPT vs. OVX+DPN treatment on the functional 
responses to VP. Similar to the mesenteric arterioles, OVX+PPT treatment resulted in a 
greater contractile force in the control response to VP. The responses to SQ and SIM in the 
OVX+PPT group were almost identical (34% reduction in contraction), unlike the 
mesenteric arterioles, where SQ did not have an effect and SIM reduced the response to VP 
by 73%. However, OVX+DPN treatment exhibited differential responses to SQ and SIM 
treatment. In the aorta, SIM reduced the response to VP by approximately 12%, whereas in 
the mesenteric arterioles, the reduction was much higher, at 92%. SQ also had a more 
prominent effect in aorta, where it reduced the maximum response to VP by 56%, while it 
had no significant effects on mesenteric arterioles. 
These data suggest that while TXA2 and TP appear to play a more significant role 
in the response to VP in aorta, the mesenteric response is either independent of TXA2 and 
TP, or the TXA2 contribution is masked by the effects of another PG, possibly PGI2. It is 
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possible that the mesenteric vasculature is more sensitive to the effects of other PGs, while 
the aorta is unresponsive to any interference of other PGs that are released, especially 
PGI2. Indeed, neither PGI2 nor PGI2 analogues produce relaxation in rat aorta (49, 107). In 
addition, aortic responses to VP appear less dependent on intracellular Ca2+ release than 
the mesenteric arterioles.  
 
5.6 Effect of Aortic Coarctation-Induced Hypertension and Estrogen Treatment 
on Estrogen Receptor Expression 
5.6.1 Real Time RT-PCR 
In the present study, there was a trend for OVX to increase the levels of ERα and 
ERβ mRNA, but there were no statistically significant differences due to animal to animal 
variability in the data.  
Other studies have shown that ERα mRNA is upregulated during OVX in the 
uterus (110) as well as in the kidney and cerebral cortex (88). However, Mohamed et al. 
(88) found that in the liver, heart, brainstem, cerebellum and thoracic and abdominal aorta 
there were no significant changes in mRNA of ERα. ERβ was not measured in these 
studies; in the Rosser study, ERβ had not yet been identified. It would appear that the 
regulation of the ERs by estrogen is tissue specific.  
While there were not any statistically different levels of mRNA in the present 
study, this may not have made much impact, since the protein expression levels for ERα 
and ERβ did not change with either estrogen treatment or hypertension, and thus, are in 
agreement with the mRNA expression data. 
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5.6.2 Immunoblots 
In the present study, there were no significant differences in the protein expression 
of the estrogen receptors; however, there were some general trends. OVX+PPT treatment 
during normotension and hypertension tended to slightly increase the expression of ERα 
when compared to INT-NT. In contrast, ERβ expression in OVX+PPT-NT, OVX+DPN-
NT, OVX+PPT-HT and OVX+PPT-NT tended to be lower than INT-NT. This might 
indicate that ERα activation increases its own receptor protein, but has little effect on ERβ 
protein levels, while activation of ERβ does not appear to affect either its own receptor 
protein or ERα protein levels. 
Previous investigations have stated that ERβ was the more dominant ER in the 
vascular system in both humans and rats (3, 57). Using the method of immunoblotting to 
detect protein levels makes comparisons between ERα and ERβ unreliable, due to 
differences in antibody binding affinity. Therefore, in the present study, we were unable to 
make such comparisons and each group is normalized to the reference group, in this case 
INT-NT.      
In the present study, levels of both ERs were strikingly similar in both INT and 
OVX groups, suggesting that the regulation of ERs is independent of ovarian function. 
Another recent study found that protein levels of ERα and ERβ in the VSM of the sheep 
uterine artery did not differ between OVX and OVX+ER sheep and that there were no 
differences in either ERα or ERβ protein in omental, renal and coronary endothelium from 
ewes in luteal, follicular and pregnant stages. An exception was the higher levels of ERβ 
protein in the coronary endothelium of pregnant ewes, compared to non-pregnant ewes 
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during the luteal phase ewes (17). An earlier study found that treatment of endothelial cells 
with 17β-estradiol decreased ERα after short-term exposure, but increased it after longer 
exposure (60). Clearly, the effect of estrogen to regulate its receptors is both tissue and 
treatment dependent. 
The lack of change in protein expression during HT likely indicates that 
upregulation of ERs in the vasculature is not the mechanism by which HT affects the PG 
pathway during the development of HT, and that changes in expression of ERs are not 
important in ACIH. However, the present study provides the unique opportunity to 
examine ER cross-regulation and protein levels in the presence of selective receptor 
activation. Specifically, whether the expression of each ER is modulated by its own 
activity, or the activity of the opposing receptor, or whether the interaction of the two ERs 
together changes their expression differentially. 
 
5.7 Conclusions  
Historically, TXA2 and other constrictor prostanoids were considered important 
only in hypertension or other vascular disease states, and only in males (22, 30, 90). More 
recent studies have revealed that not only is TXA2 important in maintaining vascular tone 
during normotension, but that the prostanoid pathway appears to contribute to vascular 
tone more in females than in males (6, 7, 8, 43, 72, 73). The findings of the present study 
confirm that ERα and ERβ contribute selectively to the actions of estrogen on the 
prostanoid pathway and are important in the regulation of constrictor prostanoid mediated 
mechanisms and blood pressure during the development of aortic coarctation-induced 
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hypertension. Further, the increased release of constrictor prostanoids by the vasculature is 
likely responsible for the increased reactivity to vasopressin seen in both the aorta and 
mesenteric vasculature (43, 73, 126, 127). Although aortic coarctation was used as the 
model of hypertension in the present study, essential human hypertension may also involve 
the effects of estrogens and constrictor prostanoids. Levels of estradiol in men and women 
with essential hypertension were higher than their normotensive counterparts (59, 65, 103), 
suggesting that estradiol may contribute to essential hypertension. In addition, aortic 
coarctation-induced hypertension is renin-angiotensin-dependent, a major factor in human 
essential hypertension as well (65, 70, 103); therefore, this model provides the unique 
opportunity to study the mechanisms of and changes to the vasculature involved in the 
development of hypertension. 
Although women appear to be protected from cardiovascular disease in the pre-
menopausal years, there is increasing evidence that the protective effects of estrogen on the 
vasculature have an “expiration date”, because post-menopausal women receiving 
hormone replacement therapy have higher incidences of cardiovascular events (51, 58, 
111) and are no longer protected.  Clearly, there are many details of current hormone 
replacement therapy which mandate investigation, including the type of hormone used, 
timing of replacement and risk factors at the time of therapy. If it is possible to separate the 
beneficial effects of estrogen from the detrimental effects, then new possibilities will 
evolve in the treatment of cardiovascular disease for women, involving selective estrogen 
receptor modulation. 
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The present study is the first to study the effects of chronic selective estrogen 
receptor stimulation during normotension and the development of aortic coarctation-
induced hypertension, and to examine the effects of the estrogen receptors on the 
production of PGI2 and TXA2, as well as the contribution of the estrogen receptors to 
vascular reactivity to vasopressin in normotension and during the development of 
hypertension. 
 The present study demonstrates that ERα mediates the majority of the effects of 
estrogen on the constrictor prostanoid pathway and on the vascular reactivity to 
vasopressin in the rat mesenteric arterioles. Although ERβ replacement therapy did not 
increase levels of PGI2 and TXA2 production to the same extent as did ERα therapy, nor 
did it increase vascular reactivity to vasopressin to the same extent, stimulation of this 
receptor caused increases in mean arterial pressure that rivaled those of 17β-estradiol and 
ERα stimulation, suggesting that ERβ affects other pathway(s) involved in this type of 
hypertension. Further investigation into the vasoconstrictor and vasodilator mechanisms 
associated with the estrogen receptors are needed to clarify the true effects of estrogen on 
vascular homeostasis and blood pressure.  
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